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ABSTRACT 
Lung cancer is the leading cause of cancer death in the United States and survival 
rates of American Indian and Alaska Native (AIAN) patients are worse than those of non-
Hispanic White (NHW) patients. A contributing factor to the worse outcomes may be 
lower healthcare utilization of AIAN patients. But improving healthcare utilization of 
AIAN to levels used comparable to those of NHW might increase costs of their care to 
amounts comparable to those of NHW. Objectives: 1) To examine differences in total 
healthcare costs and healthcare utilization  12 months following lung cancer diagnosis 
between AIAN patients and NHW patients, 2) To examine differences in total healthcare 
costs and healthcare utilization during the end-of-life period (last 6 months of life) 
between AIAN patients and NHW patients who died from lung cancer or any cause, and 
3) To compare the incidence of depression disorder 60 months after cancer diagnosis and
determine depression treatment utilization among those with a depression disorder. 
Methods:  The Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset 
was used. Patients included in the study were those age 65 years and older, diagnosed 
with lung cancer between 2000 and 2011, Part A coverage, Part B coverage and no 
managed care plan before.   Diagnosis and procedure codes were used to identify costs, 
utilization, and depression diagnoses. The propensity score matching method was used to 
balance groups. A generalized linear model (GLM) was used for costs analysis and the 
negative binomial regression model was used to analyze healthcare utilization. A Cox 
iv 
proportional hazards regression model was used to identify risk factors for new diagnosis 
of depression. Results:  Being AIAN was associated with lower total healthcare costs 12 
months following lung cancer diagnosis. In contrast, being AIAN was not associated with 
total healthcare costs six months before date of death among patients diagnosed with lung 
cancer and ≤6 month survival time. The incidence of diagnosis of depression disorder 60 
months after lung cancer diagnosis was 3.67% for AIAN patients and 6.16% for NHW 
patients. The mean number of depression treatment visits suggests higher utilization 
among AIAN patients compared with NHW patients.  AIAN patients were not at 
increased risk for depression after cancer diagnosis.  Conclusions: The healthcare 
utilization of AIAN patients with lung cancer could be improved while keeping costs of 
care no higher than those of NHW patients. But any improvements of health care use 
would need to take account of the variability among AIAN patients receiving health care 
12 months following cancer diagnosis, in the last six months of life, and after depression 
disorder diagnosis.  
Dedicated to the memories of my dad, David Harvey Jim,  
my paternal grandmother, Mary Jim, and my maternal grandfather, Keith Fatt, 
who died from cancer. 
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In the United States, lung and bronchus cancer is the leading cause of all cancer 
deaths and the second mostly commonly diagnosed cancer in women and men.1,2  In 
2017, an estimated 155,870 lung cancer deaths will occur in men and women, which is 
one lung cancer death for every four individuals.2 Twenty-five percent (222,500 new 
cases) of cancer diagnoses will be new lung cancers in 2017.2 Despite decreases in lung 
cancer incidence over time for American Indian and Alaska Native (AIAN) individuals, 
their lung cancer rates have not declined as much as non-Hispanic (NHW) individuals.3,4 
For every 100 lung cancers diagnosed, there are six more AIAN deaths than NHW 
deaths.5 
Excess risk for lung cancer and cancer deaths are often attributable to behavioral 
risk factors such as smoking. The primary risk factor for lung cancer is smoking tobacco, 
as well as a person’s cancer history, family history, age, smoking exposure, and 
occupational exposures (i.e., radon).6 Compared to other racial/ethnicity groups, AIAN 
adults report a higher prevalence of daily cigarette, cigar, and smokeless tobacco use and 
over time their decline in smoking rates has been much slower.5,7 Even more so, older 
AIAN (≥ 65 years) individuals have 10% higher odds of smoking-attributable deaths due 
to lung cancer compared with older NHW individuals.8 AIAN patients with lung cancer 
have worse outcomes. Five-year survival rates for AIAN patients for any cancer are much 
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lower (53.9%) than other racial/ethnicity groups (67.6% for NHW patients, 57.0% for 
Blacks).9 Most AIAN patients, once diagnosed with lung cancer, live with cancer fewer 
years than NHW patients.  
A smaller proportion of AIAN patients with lung cancer have surgery after cancer 
diagnosis.10-12 There are standard treatment guidelines for lung cancer patients developed 
by the National Comprehensive Cancer Network.13 Cancer-related therapy consists of 
surgery, radiation, chemotherapy, and combination treatments. Appropriate therapy 
depends on the type of lung cancer, and may differ depending on the stage at which it is 
diagnosed. For example, initial therapy for non-small cell lung cancer patients depend on 
the stage of the disease, if the tumor is small then surgery is recommended;  
a larger tumor it may require surgery followed by radiation treatment, and in some cases 
additional chemotherapy.13 Although guidelines are in place, fewer AIAN cancer patients 
than NHW cancer patients received guideline-concordant treatment after cancer 
diagnosis.10 More often these patients are diagnosed with lung cancer at stage III or IV of 
the disease, which is considered late stage.10 Lung cancer patients with a late-stage 
diagnosis are given different treatment options than those at an earlier stage  
(stage I or II diseases). 
Racial differences in health care costs and utilization of lung cancer patients have 
not been widely studied. The publications that do exist focus on either cancer-treatment 
and/or racial/ethnicity groups. In 2008, two studies using SEER-Medicare datasets 
reported trends in the cost of initial cancer treatment and costs of care for elderly patients 
in the United States. In 2002, one study showed that the total healthcare costs  
(cancer-treatment and other hospitalizations) for lung cancer patients was $39,891.14 In 
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2004, researchers defined three phases of care to describe cost implications for cancer 
patients: 1) initial phase (less than 12 months after diagnosis), 2) continuing phase 
(more than 12 months after cancer diagnosis), and 3) end-of-life phase (last 12 months of 
life).15 The mean net costs of cancer care (e.g., the difference between cancer patients and 
control subjects without cancer) for lung cancer patients with a distant stage at diagnosis 
was $42,833, while patients in the last year of life was $66,969.15 Because racial 
differences were not addressed in these publications, our research will add to their 
findings. 
Cancer patients diagnosed at a late stage (distant) for lung cancer may experience 
psychological distress leading to a depression disorder diagnosis. As worse cancer 
survival outcomes are seen in lung cancer patients with a depression disorder, more 
research was recognized by several researchers to identify incidence and prevalence rates 
for depression in cancer patients, especially in the United States.16-18 
In the United States, there are 566 federally recognized tribes. Many of those 
receive health services (including mental health services) through Indian Health Service 
(IHS) under the Indian Health Care Improvement Act in 1976 as modified and amended 
in succeeding years.19,20 Patient care provided through the IHS for the AIAN population 
is not an entitlement program like Medicare, Medicaid, or Social Security with a budget 
proportional to the population that is entitled to the benefits. Instead, the IHS has a 
budget that changes little from year to year as the AIAN population grows. There are 
limits on the amount of health care that can be provided to the AIAN population, though 
since 1976 the AIAN population may apply for Medicaid or Medicare like other US 
citizens.  The IHS has a limited number of health care providers located on or near tribal 
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lands that provide mainly primary care. In the 2010 census, there was an estimated 76% 
of AIAN individuals residing off a Tribal Reservation.21 In order to maintain eligibility 
for IHS, a patient has to reside within the IHS boundaries and if a patient relocates 
eligibility is loss after three months.22 Figure 1.1 shows the IHS boundaries by Contract 
Health Service Delivery Areas.23  Although the IHS receives federal funding to give 
tribes for medical services not provided by IHS health care facilities, there is never 
enough to cover the needs of all patients. IHS health care facilities encourage Medicare 
enrollment of eligible AIAN so facilities can be reimbursed for treatment they provide.   
AIAN cancer patients with Medicare or other health care coverage receive health 
services on and off the tribal reservations and they often require cancer-treatment at non-
IHS facilities. The Centers for Medicare and Medicaid Services (CMS) is an agency 
committed to providing a health insurance program for people older than 65 years old, 
people under age 65 with certain disabilities, and those with End-Stage Renal Disease at 
any age. CMS works with tribes through meaningful consultation and a Tribal Advisory 
Group to assure access to care for AIAN elders and to increase capacity of Indian Health 
Service to deliver integrated and comprehensive programs.24 Effective policies are 
extremely important regarding enrollment, access to care, coordinated care, integrated 
services, coverage, and benefits for AIAN elderly patients with lung cancer, since their 
health needs differ from other Medicare enrollees.  
Investigating healthcare costs and utilization differences among AIAN and NHW 
patients with lung cancer could determine whether an AIAN individual get less treatment 
at lower costs. Understanding healthcare costs and utilization differences among AIAN 
and NHW patients with lung cancer will provide a foundation for further research and an 
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evaluation of cancer care disparities. This dissertation focused on three specific aims.  
In the first specific aim, we will examine whether there are differences in total 
healthcare costs and healthcare utilization 12 months following lung cancer diagnosis 
between AIAN and NHW patients. The hypotheses are that total healthcare costs and 
healthcare utilization are higher for NHW patients compared with AIAN patients with 
lung cancer.  
In the second specific aim, we will examine differences of total healthcare costs 
and healthcare utilization during the end-of-life period (last six months of life) between 
AIAN and NHW patients who died from lung cancer or any cause. The hypotheses are 
that total healthcare costs and healthcare utilization are higher for NHW patients during 
the end-of-life period compared with AIAN patients with lung cancer.  
The third specific aim is to compare the incidence of depression disorder 60 
months after cancer diagnosis and to determine depression treatment utilization among 
those with depression disorder. We will further determine the risk factors for depression 
disorder among lung cancer patients. The hypotheses are that incidence of depression 
disorder is higher in AIAN patients and that there is less depression treatment utilization 






Figure 1.1 Indian Health Service Areas by Contract 
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While disparities in lung cancer survival outcomes of American Indian and 
Alaska Native (AIAN) patients compared to non-Hispanic White (NHW) patients are 
documented, little is known of disparities in health care among AIAN and NHW patients 
with lung cancer that could contribute to these disparities in outcome, nor what the costs 
might be of reducing any disparities in health care.  Objective: We examined total 
healthcare cost and utilization (for cancer- and noncancer-treatment) differences among 
AIAN patients and NHW patients 12 months after lung cancer diagnosis. Methods:  We 
used the Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset and 
identified 126,725 patients diagnosed from January 1, 2000 to December 31, 2011. There 
were 1,254 patients matched on patient characteristics and cancer prognosis. To identify 
total healthcare costs and total healthcare utilization based on cancer and noncancer-
treatment, we used diagnosis and procedure codes. To examine total healthcare costs 
between American Indian and Alaska Native patients and non-Hispanic White patients, 
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we used a generalized linear model with gamma distribution and log link. To examine 
healthcare utilization, we used a negative binomial regression Model. Results: American 
Indian and Alaska Native patients used significantly less health care (p < 0.01) compared 
with non-Hispanic White patients. Being an American Indian and Alaska Native patient 
was also associated with lower total healthcare costs (p = 0.01) adjusting for patient 
characteristics and cancer prognosis. An analysis of cancer-treatment and noncancer-
treatment costs showed that being an American Indian and Alaska Native patient was 
associated with lower cancer-treatment costs, but not noncancer-treatment costs. 
Conclusion: Healthcare disparities exist between AIAN and NHW lung cancer patients, 
with lower costs of cancer care among the AIAN patients indicating that increased costs 





In the United States, cancer costs continue to increase annually in part due to new 
treatments, an aging population, and longer survival among those with cancer.14,25 Cancer 
care expenditures from 1998 to 2000 was $94.6 billion and by 2010 it was $133.7 billion.25 
In 2014, across several payment sources for cancer care, 38% of costs were covered by 
Medicare and 44% of costs by private payers.25 Payment sources for health services often 
entail private insurance, patients and their families (out-of-pocket), and public plans such 
as Medicare and Medicaid.  
Among Medicare patients, the average cost of lung cancer treatments was greater 
than those of breast and prostate cancer treatments.14 Yabroff and researchers15 reported 
that lung cancer patients with Medicare coverage and late-stage diagnosis have higher net 
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costs of lung cancer care in the initial phase (12 months following cancer diagnosis). 
Additionally, Warren and researchers14 reported that an increase in cancer-treatment costs 
during the initial phase are related to surgery and adjuvant therapy ($12,712 for cancer-
related surgery and $23,026 for chemotherapy vs. $12,712 for surgery). 
In 2017, an estimated 155,870 lung cancer deaths will occur in men and women, 
which is the equivalent of one cancer death for every four individuals.2 Twenty-five 
percent (222,500 new cases) of cancer diagnoses will be new lung cancers in 2017. Over 
the course of a decade (1999 to 2009), 8,118 AIAN persons died from lung cancer in the 
United States.5 Most important, in Indian Health Service areas cancer deaths vary. AIAN 
patients have higher lung cancer deaths compared with NHW persons across several 
areas throughout the nation, such as Northern Plains, Alaska, Southern Plains, and the 
Pacific Coast.5  
Little is known about differences in total healthcare cost and utilization for AIAN 
patients and NHW patients after diagnosis with lung cancer. This study contributes to 
recent broader studies of healthcare cost and healthcare utilization by focusing on AIAN 
and NHW lung cancer patient costs reflecting cancer and noncancer-treatment care.14,15 
Specifically, we examined healthcare cost and utilization 12 months after cancer 
diagnosis date for AIAN and NHW patients diagnosed with lung cancer between 2000 
and 2011. The hypotheses in this study were that NHW patients would have higher levels 
of healthcare utilization and therefore accrue higher healthcare costs compared with 








2.3.1 Study Design and Data Source 
 
This study was a cohort design using the Surveillance, Epidemiology, and End 
Results (SEER)-Medicare dataset from 2000 to 2012. SEER-Medicare is a population-
based resource often used cancer epidemiology and health services research. The SEER-
Medicare database represents 26% of the United States population and 42% of the AIAN 
population aged 65 and older based on SEER registry locations.10 This study utilized data 
from SEER registries in Connecticut, Detroit, Greater California, Greater Georgia, 
Hawaii, Iowa, Kentucky, Louisiana, Los Angeles, Michigan, New Jersey, New Mexico, 
Rural Georgia, San Francisco-Oakland, San Jose-Monterey, Seattle-Puget Sound, and 
Utah. The SEER-Medicare dataset was a linked dataset by using a unique patient 
identification number in the SEER Registry and Medicare claims. Several files from 
SEER-Medicare were used in this study: Durable Medical Equipment (DME), Home 
Health (HHA), Medicare Provider Analysis and Review (MEDPAR), National Claims 
History (NCH, previously known as Physician/Supplier), Outpatient (OUTSAF), and 
Patient Entitlement and Diagnosis File (PEDSF). 
 
2.3.2 Study Population 
 
Non-Hispanic White and AIAN Medicare enrollees aged 65 years or older with a 
first primary cancer date of diagnosis between January 1, 2000 and December 31, 2011 of 
lung and bronchus cancer (e.g., ICD-O codes C34.0-C34.3, C34.8, C34.9) and stages IA 
to IV (as defined by the American Joint Committee on Cancer) were included. Further 
inclusion criteria were patients with continuous enrollment in Part A and Part B six 
months prior to cancer diagnosis date and from the cancer diagnosis date to 12 months 
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after cancer diagnosis. If the patient died within those timeframes, they were still 
included in the study. 
The following are exclusions of patients based on Medicare enrollment, histology 
and date of cancer diagnosis. Patients were excluded based on Medicare eligibility status 
as a managed care plan and/or absence of any Part A (inpatient claims) and Part B 
(outpatient claims) coverage six months prior to and 12 months following cancer 
diagnosis. Patients with the following lung cancer histology codes were excluded due to 
location of tumor on skin or gastrointestinal tract: 8585/3 Thymoma, malignant; 8720/3 
Malignant melanoma; 8770/3 Mixed epithelial and spindle cell melanoma; 9650/3 
Hodgkin lymphoma; 9680/3 Diffuse large B cell; and 9699/3 Marginal zone B-cell 
lymphoma. Patients with a diagnosis date at death or autopsy, a cancer diagnosis date 
after date of death, or a cancer diagnosis date prior to age 65 years were excluded. 
Prescription drugs claims were not included in this study. The resulting sample size for 
this study was 443,691 patients and 316,964 patients were excluded for the reasons 
above. The sample for this study was 126,725 (434 AIAN patients and 126,291 NHW 
patients) (see Figure 2.1). The final sample after matching was 418 AIAN patients and 
836 NHW patients. 
 
2.3.3 Propensity Score Method 
 
We used the propensity score methodology developed by Rosenbaum and Rubin 
who described propensity scores as the probability of treatment assignment conditional 
on observed baseline covariates.26 The propensity scores were applied to improve 
adjustment of confounders, such as marital status and disease attributes, and to establish 
similar matched controls (matching NHW patients to the AIAN patients). Although it is 
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important to note that hidden bias (unmeasured confounders) cannot easily be detected 
using this method.27,28 
In this study, logistic regression was used to estimate propensity scores for each 
patient. The covariates were age at diagnosis, sex, year of diagnosis, stage of disease, 
grade, histology, Charlson Comorbidity Index, SEER registry, and marital status. The 
dependent variable was outpatient and inpatient costs. The Charlson Comorbidity Index 
was derived from physician claims of comorbid conditions.29-31 The focus of the study 
consists of lung cancer patients; therefore, cancer diagnosis was excluded from the 
Charlson Comorbidity Index.32 The PSMATCH2 in STATA was used for propensity 
scoring matching of 1:2 ratio without replacement.28,33,34 To determine similarities, we 
assessed the balance of covariates, the continuous and categorical covariates means and 
proportions were compared using the Harder, Stuart, and Anthony method along with the 
standardized bias cutoff of 0.10.28 
 
2.3.4 Definition of Total Healthcare Cost 
 
Total healthcare costs were examined for the 12-month period after cancer 
diagnosis. To identify total healthcare costs the Current Procedural Terminology (CPT); 
Healthcare Common Procedure Coding System (HCPCS); International Classification of 
Diseases; Ninth Revision (ICD-9); and revenue codes were used (see Table 2.1). The 
DME, HHA, MEDPAR, NCH, and OUTSAF files were used to estimate total healthcare 
costs. All healthcare costs for each outpatient and inpatient visit were assessed from the 
patient’s admission date. Total healthcare cost consists of cancer-treatment and 




The three payment sources used to identify total healthcare costs in the SEER-
Medicare files are Medicare, coinsurance, and patient responsibility. Medicare costs are 
reimbursed amounts. Coinsurance consists of payments by a primary payer other than 
Medicare. Patient responsibility was defined as the beneficiary’s liability for payment.  
Total healthcare cost was defined as the sum of cancer-treatment and noncancer-
treatment costs. Inpatient, outpatient, and emergency department costs were identified 
from the NCH file. Part A claims using the Centers for Medicare and Medicaid Services 
(CMS) Inpatient Hospital Index and Part B claims were adjusted using the Medicare 
Economic Index.35 All costs were reported in 2012 dollars as this was the most recent 
diagnosis year in the SEER-Medicare dataset. 
 
2.3.5 Definition of Total Healthcare Utilization 
 
Total healthcare utilization was examined for the 12-month period after the cancer 
diagnosis. Total healthcare utilization is defined as the sum of cancer-treatment 
encounters and noncancer-treatment encounters. The NCH file was used to identify 
patient encounters. Encounters were comprised of inpatient (Part A), outpatient (Part B), 
and emergency department visits (Part B). To identify encounters, the ICD-9, revenue, 
HCPCS, and CPT codes were used. Total healthcare visits were based on a patient’s 




The PEDSF file was used to identify the patient’s age at diagnosis, year of 
diagnosis, sex, stage of disease, grade, histology, SEER registry at diagnosis, and marital 
status. The NCH file was used to identify Charlson Comorbidity Index scores. 
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2.3.7 Statistical Analysis 
 
To describe patient characteristics, the chi-square test was used to determine 
NHW versus AIAN cohort differences for binary and categorical variables. The 
independent t test was used to examine the differences of continuous variables between 
the cohort groups. Statistical significance was defined as p < 0.05. STATA version 14.0 
(Stata Statistical Software: Release 14. College Station, TX: StataCorp LP) was used for 
all analyses. To examine the possible associations between total healthcare costs and 
other variables, the generalized linear model (GLM) with log link and gamma 
distribution was applied due to positive skewness of cost data. To examine the 
associations of healthcare utilization with other variables and due to the over-dispersion 
(if the variance is larger than the mean of a Poisson distribution) of total healthcare 
utilization, a negative binomial regression model (NBRM) was used in the unadjusted 




A total of 126,725 of first primary lung cancer patients 65+ years of age were 
included in the cohort study: 434 cases were AIAN patients and 126,291 were NHW 
patients (see Table 2.2). Before patients were matched, age at lung cancer diagnosis  
(p = 0.01), stage of disease (p = 0.02), histology (p = 0.02), marital status (p < 0.01), and 
SEER registry residence (p < 0.01) differed between AIAN patients and NHW patients, 
such that AIAN patients had more adenocarcinoma cancer (28%), were not married 
(47%), and resided mainly in the West US census region (79%). Grade (p = 0.10), gender 
(p = 0.87), Charlson Comorbidity Index (p = 0.35), and census metro residence (p < 0.01) 
did not differ between AIAN and NHW patients. Among NHW and AIAN patients, there 
15 
were more patients between age 65 and 70 years (32% AIAN, 29% NHW) with stage IV 
disease (47% AIAN vs. 36% NHW), and who resided in metro areas (78% AIAN versus 
80% NHW). 
Once patients were matched, the propensity scores for all covariates met the 10% 
standardized bias criteria between AIAN and NHW patients (see Figures 2.2 and 
2.3).27,28 In the matched sample, 418 AIAN patients were matched to 833 NHW patients 
(see Table 2.2). As a result, the unadjusted difference in mean total healthcare costs after 
matching was    -$4,784 ($39,371 versus $44,155 for AIAN and NHW, respectively) 
(see Table 2.3). In Table 2.4 the unadjusted difference in mean total healthcare 
utilization after matching was -4 visits (40 versus 44 visits for AIAN and NHW, 
respectively).  
2.4.1 Unadjusted Total Healthcare Costs 
In the matched sample, the unadjusted log coefficients show that being an AIAN 
was associated with lower total healthcare costs (coefficient = -0.13, p = 0.02). 
2.4.2 Adjusted Total Healthcare Costs 
In the adjusted GLM, being an AIAN patient was associated with a 13% 
decrease in average healthcare costs (coefficient=-0.13, p = 0.02) and a 20% decrease in 
average cancer-treatment costs (coefficient=-0.20, p = 0.05) after adjusting for 
demographics, survival time, cancer prognosis, and comorbidities (see Table 2.5 and 
Table 2.6). In contrast, being an AIAN was a not associated with total noncancer-
treatment costs (coefficient=-0.10, p = 0.06) after adjusting for demographics, survival 
time, cancer prognosis, and comorbidities (see Table 2.7).  
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2.4.3 Unadjusted and Adjusted Healthcare Utilization 
 
In the unadjusted model, AIAN patients had a 12% lower healthcare use 
compared with NHW patients (coefficient = -0.11, p = 0.02). In the adjusted model, 
AIAN patients used significantly less healthcare compared with NHW patients  
(coefficient = -0.12, p = 0.01). Patients with stage II disease compared with stage III and 
IV disease, while holding other variables constant, had a rate 1.30 times greater 
healthcare visits for patients. Divorced, separated, and widowed patients compared with 
single and married patients, while holding other variables constant, had a rate of 0.81 
times less healthcare visits (see Table 2.8). 
 
2.4.4 Cancer- and Noncancer-Treatment Care 
In this study, more than half of total healthcare costs for AIAN (54%) and NHW 
patients (52%) with lung cancer were for noncancer-treatment in inpatient care. While 
most (more than 90%) cancer-treatment costs from AIAN and NHW patients were for 
outpatient care. Sixty-five percent of cancer-treatment costs by AIAN patients were from 
chemotherapy, as well, 3% from surgery and 40% from radiation therapy. For NHW 
patients, 72% of cancer-treatment costs were from chemotherapy, as well, 4% from 




AIAN patients had lower total healthcare costs within the 12-month period after 
cancer diagnosis.  In addition, being AIAN was associated with lower cancer-treatment 
costs, while being AIAN were not associated with total noncancer-treatment costs. As far 
as healthcare utilization, AIAN lung cancer patients was associated with lower  
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healthcare utilization. To our knowledge, this is the first study to examine patterns of 
healthcare costs and healthcare utilization among older AIAN patients with lung cancer.  
 
2.5.1 Total Healthcare Costs 
 
The overall mean total healthcare cost in this study was lower than those reported 
in other SEER-Medicare studies that investigated the costs of cancer or costs of care (i.e., 
the difference in costs between cancer and noncancer patients).14,15 The mean total 
healthcare costs were lower in our study compared with lung cancer patients investigated 
by Yabroff and researchers15 12 months following cancer diagnosis ($39,180 for AIAN 
and $43,844 for NHW lung cancer patients in our study compared to $45,524 in the 
Yabroff study,15 adjusted to 2012 dollars). Yabroff and colleagues15 included hospice 
estimates (i.e., 12 months following cancer diagnosis) that may suggest higher costs 
compared to this study. They were able to identify costs of care, but didn’t control for 
confounders or addressed racial/ethnic differences. We evaluated differences in costs 
among AIAN and NHW lung cancer patients and within these differences the proportion 
of higher noncancer-treatment costs compared to cancer-treatment costs were known; 
however, the proportion of patients with cancer-treatment costs was not tested for 
statistical significance in this study.  
Warren and researchers examined the costs of cancer-treatment 12 months 
following lung cancer diagnosis using SEER-Medicare and reported fewer than 50% of 
patients received cancer-treatment.14 Although we did not examine differences in 
proportion of patients who used services, we are able to report cancer-treatment costs in 
relation to total healthcare costs. In contrary, the percent of total healthcare costs suggest 
that less than 72% of chemotherapy spending were from AIAN lung cancer patients in 
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the matched sample. As well, close to half of the total healthcare spending was from 
inpatient care for noncancer-treatment by AIAN lung cancer patients. These results 
illustrate a shift in costs of noncancer-treatment costs in inpatient care than cancer-
treatment costs.  
 
2.5.2 Total Healthcare Utilization 
 
AIAN patients received fewer health services (i.e., inpatient and outpatient care) 
than NHW lung cancer patients 12 months following cancer diagnosis. Due to the limited 
studies of healthcare utilization for lung cancer patients following cancer diagnosis, 
comparability to other studies is not addressed, rather the need for further research is 
strongly recommended.  In this study, the results suggest higher inpatient care spending 
from noncancer-treatment care. On average, aging adults with cancer accrue more costs 
and patient time for hospitalizations, emergency room visits, ambulatory surgeries, and 
physician visits than patients without cancer.36 Although we are capturing comorbidities 
six months before cancer diagnosis, this time period may not detect long-term chronic 
health conditions that may suggest higher noncancer-treatment costs after cancer 
diagnosis. Our findings provide healthcare utilization in conjunction with healthcare costs 
for lung cancer patients in one cohort.  
A strength of this study is consideration of both cancer-treatment and noncancer-
treatment care for AIAN and NHW lung cancer patients. Most importantly, patterns 
suggest that healthcare costs and utilization are lower for AIAN patients. Both cohort 
groups portrayed similar trends, the results suggest higher health spending from 
noncancer-treatment than cancer-treatment care. In prior cost studies using SEER-
Medicare, racial/ethnic differences were not well represented and an inclusion of 
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noncancer-treatment costs that augments complete patient care 12 months following 
cancer diagnosis. Significant differences in healthcare costs and utilization among AIAN 
patients is concerning in this study. One study reported that AIAN cancer patients 
(including lung cancer) who trust their provider adhered to guideline-concordant 
treatment more often.40 Other research in understanding access to and use of treatment by 
AIAN is positive and indicates progress toward improving treatment, and thus potentially 
survival outcomes, for AIAN patients with cancer.  
There are several limitations of this study. Retrospective studies like this study 
rely on detailed data on patients, but use of claims data does not include provider notes 
on treatment intentions or other information regarding patient care. Additional provider 
information may support assumptions about access to care issues, such as refusals or 
provider-patient decision making. Out-of-pocket expenses were captured as part of total 
healthcare costs in this study, but information about receipt of payment is not reported. 
Most AIAN patients in this study are from lower income census regions. However, it’s 
not known if other financial support assistance existed that contributed to their out-of-
pocket expenses. For AIAN patients on Medicare, more than 28% have no supplemental 
coverage and are at risk for out-of-pocket sharing requirements.41 Also, payments made 
by the Indian Health Service for cancer-treatment and noncancer-treatment are not linked 
to SEER-Medicare, thus Medicare cost estimates may not reflect all sources of payments. 
Geographically, representation of AIAN patients who utilize IHS facilities is limited 
since IHS Contract Health Service Delivery Areas are not aligned with SEER registry 
locations. Race misclassification is possible, since Medicare uses self-reported 
information, while SEER registries obtain race information from providers.  
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In summary, the results in this study suggest that AIAN patients with lung cancer 
use less care resulting in fewer costs for overall healthcare services. Since survival rates 
of AIAN patients with lung cancer are lower than other racial and ethnic groups, there 
should be further research of cancer-treatment utilization among AIAN patients with lung 
cancer.  The possibility remains that increased resources applied to the care of AIAN 
patients with lung cancer could potentially reduce disparities between AIAN and White 
patients with lung cancer not only in use of care, but survival as well.   The mix of 
resources from Medicare, Indian Health Service, State, Federal, and Tribal agencies for 
tribal AIAN needs to be better understood since tribal and nontribal AIAN patients are 






Figure 2.1 Inclusion and Exclusions Diagram 
 




Figure 2.2 Percent of Standardized Bias Differences for  
Propensity Score Matching in Group One. 
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Figure 2.3 Percent of Standardized Bias Differences for  
Propensity Score Matching in Group Two. 
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Diagnostic and Procedure Codes 
 
 
Items Diagnostic and Procedure Codes 
Radiation Therapy 
ICD-9 9221 9222 9223 9224 9225 9226 9227 9228 9229 923 9231 9232 9233 9239 
 
CPT V580 V661 V671 7637 76370 77014 76950 7695 77261 77280 7728 77285 77290 7729 
77295 77299 7730 77300 77301 77305 77310 7731 77315 77321 77326 77327 77328 
77331 77332 7333 77334 77336 77370 77371 7737 77372 77373 77399 77401 77402 
77403 77404 77406 77407 77408 77409 77411 77412 77413 77414 77416 77417 77418 
7742-77425 77427 77431 77432 77435 77469 77470 77499 77520 77522 7752 77523 
77525 77615 77750 77761 77762 77763 77770 77771 77772 77776 77777 77778 77781-
77787 77789 77799 
 
HCPCS G0173 G0251 G0339 G0340 G034 G0256 G0261 G6015 C1717 C1719 C2638 C2640 
C2641 
 
Revenue 330 333 
 
Surgery  
ICD-9 3201 3209 321 322 3223 3224 3225 3226 3228 3229 323 324 325 3259 329 344 
 
CPT  19260 19271 19272 31640 31641 31643 32100 32440 32442 32445 32480 32482 
32484 32486 32488 32500 32520 32522 32525 32657 
 
Chemotherapy 
ICD-9  3492 9925 V581 v5810 v5811 v662 v6620 v672 v6720 
 
CPT  36260 3626 95990 9599 95991 96400 964 9640 96405 96406 96408 96410 9641 96412 
96414 96420 9642 96422 96423 96425 96440 9644 96445 96450 96520 9652 96530 96542 
96545 96549 
 
HCPCS A4301 C9411 C9414 E0782 E0783 E0784 E0785 E0786 E0873 E0874 G0355 G0356 
G0357 G0358 G0359 G0360 G0361 G0362 G0363 J0207 J0640 J0880 J1190 J1440 J1950 
J2405 J2430 J2505 J2820 J3487 J8520 J8521 J8530 J8560 J8565 J8600 J8610 J8700 J8999 
J9000 – J9999 K0415 K0416 Q0083 Q0084 Q0085 Q0136 Q0137 Q0179 S0177 S0181 
 
Revenue 331 332 335 
 
Note. ICD = International Classification of Disease, 9th Edition; HCPCS = Healthcare Common Procedure 










N = 434 
% 
NHW 
N = 126,291 
% p Value 
AIAN  
N = 418 
% 
NHW 
N = 836 
% p Value 
Age at Diagnosis (mean) 74  75  0.01 74  74  0.75 
   65-70  141 32.49 36,071 28.56  136 32.54 284 34.09  
   71-75  124 28.57 33,402 26.45  117 27.99 233 27.97  
   76-80  93 21.43 29,363 23.25  90 21.53 181 21.73  
   81+  
 
76 17.51 27,455 21.74 0.06 75 17.94 135 16.21 0.87 
Year of Diagnosis           
   2000 – 2005 200 46.08 62,047 49.13  194 46.41 376 44.98  
   2006 – 2011 
 
234 53.92 64,244 50.87 0.21 224 53.59 460 55.02 0.63 
AJCC 6th Stage of Disease           
   Stage I  69 15.90 27,743 21.97  64 15.31 148 17.70  
   Stage II  24 5.53 5,496 4.35  23 5.50 35 4.19  
   Stage III 137 31.57 36,322 28.76  133 31.82 235 28.11  
   Stage IV  
 
204 47.00 56,730 44.92 0.02 198 47.37 418 50.00 0.30 
Histology Type           
   Adenocarcinoma  122 28.11 44,982 35.62  117 27.99 240 28.71  
   Large Cell  15 3.46 4,675 3.70  15 3.59 37 4.43  
   Non-Small Cell  74 17.05 17,305 13.70  70 16.75 113 13.52  
   Small Cell  72 16.59 18,522 14.67  71 16.99 140 16.75  
   Squamous Cell  109 25.12 28,159 22.30  106 25.36 208 24.88  
   Other Type  
 
42 9.68 12,648 10.01 0.02 39 9.33 98 11.72 0.55 
Grade           











N = 434 
% 
NHW 
N = 126,291 
% p Value 
AIAN 
N = 418 
% 
NHW 
N = 836 
% p Value 
   Moderately 
Differentiated  52 11.98 19,109 15.13  50 11.96 98 11.72  
   Poorly Differentiated  104 23.96 31,371 24.84  104 24.88 219 26.20  
   Undifferentiated  32 7.37 7,742 6.13  30 7.18 62 7.42  
   Cell Type Unknown 
 





0.02  0.03  0.35 0.02  0.02  0.93 
Gender           
   Male  227 52.30 65,568 51.92  220 52.63 431 51.56  
   Female  
 
207 47.70 60,723 48.08 0.87 198 47.37 405 48.44 0.72 
Census Tract Metro 
Residence           
   Metro  337 77.65 100,458 79.54  323 77.27 654 77.27  
   Nonmetro  97 22.35 25,826 20.45  95 22.73 182 21.77  
   Missing 
 
0 0.00 7 0.01 0.61 0 0.00 0 0.00 0.70 
Marital Status           
   Married  176 40.55 65,452 51.83  176 42.11 346 41.54  
   Single 38 8.76 8,165 6.47  38 9.09 69 8.28  
   Divorced 204 47.00 48,244 38.20  204 48.80 418 50.18  
   Missing 
 
16 3.69 4,430 3.51 <0.01 0 0.00 0 0.00 0.84 
US Census Region           










N = 434 
% 
NHW 
N = 126,291 
% p Value 
AIAN 
N = 418 
% 
NHW 
N = 836 
% p Value 
   Midwest 35 8.06 18,008 14.26  34 8.13 130 15.55  
   South 26 5.99 39,780 31.50$6  26 6.22 199 23.80  
   West 
 
344 79.26 42,630 33.76 <0.01 329 78.71 360 43.06 <0.01 











American Indian and Alaska Native Non-Hispanic White 
Mean $ Median $ 
Range $  
(min–max) 
Mean $ Median $ 
Range $ 
(min–max) 
Unmatched (AIAN = 434, NHW = 126,291)      
Cancer-Treatment       
Inpatient 568 0 0-15,795 674 0 0-182,457 
Outpatient 9,071 1,166 0-115,601 9,885 1,977 0-477,047 
Emergency Room - Hospital 8 0 0-336 6 0 0-5,557 
Surgery 288 0 5,029 463 0 0-182,457 
Radiation Therapy 3,850 0 0-49,090 3,482 0 0-159,478 
Chemotherapy 6,331 0 0-107,491 7,265 0 0-477,047 
Total Cancer-treatment 
 
9,713 2,720 0-116,184 10,668 3,302 0-477,047 
Noncancer-Treatment       
Inpatient 21,234 16,205 0-293,821 21,827 15,567 0-664,007 
Outpatient 6,322 4,474 0-85,210 7,072 4,920 0-247,303 
Emergency Room - Hospital 272 179 0-3,670 221 144 0-7,082 
Total Noncancer-Treatment 29,382 22,508 0-321,104 30,905 23,467 0-665,432 
 
Total Healthcare Treatment Cost 
 
39,095 31,188 0-344,978 41,573 32,610 0-665,432 
Matched (AIAN = 418, NHW = 836)      
Cancer-Treatment       
Inpatient 573 0 0-15,795 761 0 0-62,039 
Outpatient 9,134 1,599 0-115,601 10,901 2,333 0-202,374 
Emergency Room – Hospital 7 0 0-336 8 0 0-549 
Surgery 286 0 0-5,029 433 0 0-15,426 









American Indian and Alaska Native Non-Hispanic White 
Mean $ Median $ 
Range $ 
(min–max) 
Mean $ Median $ 
Range $ 
(min–max) 
Chemotherapy 6,366 0 0-107,491 8,484 0 0-202374 
Total Cancer-Treatment 
 
9,782 2,990 0-116,184 11,789 3,763 0-202,374 
Noncancer-Treatment       
Inpatient 21,333 16,250 0-293,821 22,983 17,046 0-237,912 
Outpatient 6,445 4,570 0-85,210 7,358 5,244 0-77,596 
Emergency Room – Hospital 271 178 0-3,670 242 161 0-1,546 
Total Noncancer-Treatment 29,589 22,570 0-321,104 32,482 26,032 0-262,697 
 
Total Healthcare Treatment Cost 
 





























Unmatched (AIAN = 434, NHW = 126,291)     
 
Cancer-Treatment       
Inpatient 0.48 0 0-31 0.62 0 0-82 
Outpatient 8 1 0-90 8 1 0-253 
Emergency Room - Hospital 0.03 0 0-2 0.02 0 0-12 
Total Cancer-Treatment Visits  
 
8 2 0-91 8 2 0-269 
Noncancer-Treatment       
Inpatient 11 8 0-164 12 8 0-350 
Outpatient 16 12 0-79 19 16 0-198 




31 28 0-227 36 31 0-359 
Total Healthcare Visits  
 
40 35 0-271 44 38 0-361 
Matched (AIAN = 418, NHW = 836)      
 
Cancer-Treatment       
Inpatient 0.48 0 0-31 0.66 0 0-22 
Outpatient 8 1 0-90 8 1 0-98 


























Total Cancer-Treatment Visits  8 2 0-91 9 2 0-107 
Noncancer-Treatment       
Inpatient 11 8 0-164 12 9 0-127 
Outpatient 17 12 0-79 19 17 0-90 




32 29 0-227 36 31 0-183 
Total Healthcare Visits  
 










Adjusted Generalized Linear Model of Total Healthcare Costs 
 
 
Covariates (N = 1,254) Coefficient(β) exp(β) 95% CI p Value 
American Indian and  
  Alaska Native Race 
 
-0.12 0.80-0.98 0.02 
Age at Diagnosis    
  65-70 Reference   
  71-75 -0.08 0.83-1.04 0.20 
  76-80 -0.22 0.71-0.91 <0.01 
  81+ -0.35 0.61-0.81 <0.01 
 
Female 0.06 0.96-1.17 0.24 
 
Grade    
  Well Differentiated  Reference   
  Moderately  
   Differentiated  0.09 0.82-1.46 0.55 
  Poorly Differentiated  0.08 0.82-1.43 0.57 
  Undifferentiated  -0.07 0.68-1.30 0.68 
  Cell Type Unknown 0.05 0.81-1.40 0.66 
 
AJCC 6th Stage of  
  Disease 
   
  Stage I Reference   
  Stage II 0.34 1.11-1.79 0.01 
  Stage III 0.23 1.08-1.46 <0.01 
  Stage IV 0.12 0.97-1.30 0.12 
Histology Group    
  Adenocarcinoma  Reference   
  Large Cell  -0.12 0.70-1.13 0.34 
  Non-Small Cell  -0.04 0.83-1.12 0.61 
  Small Cell  -0.09 0.78-1.06 0.24 
  Squamous Cell  -0.03 0.85-1.11 0.67 










Table 2.5 Continued 
 
 
Covariates (N = 1,254) Coefficient(β) (β) 95% CI p Value 
Marital Status    
   Married, Domestic  
      Partner 
Reference 
0.84-1.19 0.98 
   Divorced, Widowed, 
Separated 
 
-0.14 0.78-0.97 0.01 
Survival Time 
 
0.00 0.99-1.00 0.16 
Constant 
 
10.70   
  Note. Statistically significant at alpha level of 0.05; exp(β) = exponent of log coefficient; 






Adjusted Generalized Linear Model of Total Cancer-Treatment Costs 
 
 
Covariates (N = 1,254) Coefficient(β) exp(β) 95% CI p Value 
American Indian and  
  Alaska Native Race 
 
-0.20 0.66-1.00 0.05 
 
Age at Diagnosis    
  65-70 Reference   
  71-75 -0.20 0.64-1.04 0.10 
  76-80 -0.35 0.54-0.92 0.01 
  81+ -0.69 0.37-0.67 <0.01 
 
Female 0.10 0.89-1.36 0.37 
 
Grade    
  Well Differentiated  Reference   
  Moderately 
Differentiated  
0.49 0.89-2.98 0.11 
  Poorly Differentiated  0.42 0.86-2.70 0.15 
  Undifferentiated  0.46 0.80-3.12 0.19 
  Unknown 0.39 0.83-2.61 0.19 
 
AJCC 6th Stage of  
  Disease 
  
 
  Stage I Reference   
  Stage II 0.70 1.21-3.32 0.01 
  Stage III 0.77 1.60-2.93 <0.01 
  Stage IV 0.57 1.32-2.39 <0.01 
 
Histology Group    
  Adenocarcinoma  Reference   
  Large Cell  0.07 0.65-1.76 0.80 
  Non-Small Cell  0.09 0.79-1.50 0.58 
  Small Cell  0.27 0.95-1.79 0.10 
  Squamous Cell  0.04 0.80-1.36 0.75 











Table 2.6 Continued 
 
 
Covariates (N = 1,254) Coefficient(β) (β) 95% CI p Value 
Marital Status    
   Married, Domestic,   
      Partner 
Reference  
 
   Single -0.44 0.45-0.92 0.02 
   Divorced, Widowed, 
Separated 
 
-0.36 0.56-0.87 <0.01 
 
Survival Time  
 




8.60   
   Note. Statistically significant at alpha level of 0.05; exp(β) = exponent of log coefficient; 





Adjusted Generalized Linear Model of Total Noncancer-Treatment Costs 
 
 
Covariates (N = 1,254) Coefficient(β) exp(β) 95% CI p Value 
American Indian and 
Alaska Native Race 
 
-0.10 0.82-1.01 0.06 
 
Age at Diagnosis    
  65-70 Reference   
  71-75 -0.05 0.84-1.08 0.43 
  76-80 -0.16 0.75-0.98 0.02 
  81+ -0.26 0.67-0.90 <0.01 
 
Female 0.05 0.94-1.17 0.38 
 
Grade    
  Well Differentiated  Reference   
  Moderately  
     Differentiated  -0.04 0.71-1.32 0.82 
  Poorly Differentiated  0.00 0.74-1.34 0.99 
  Undifferentiated  -0.20 0.58-1.16 0.26 
  Unknown -0.04 0.71-1.29 0.78 
 
AJCC 6th Stage of  
  Disease    
  Stage I Reference   
  Stage II 0.23 0.97-1.63 0.08 
  Stage III 0.01 0.86-1.18 0.91 
  Stage IV -0.06 0.80-1.10 0.43 
 
Histology Group    
  Adenocarcinoma  Reference   
  Large Cell  -0.23 0.61-1.03 0.08 
  Non-Small Cell  -0.07 0.79-1.10 0.42 
  Small Cell  -0.21 0.69-0.96 0.02 
  Squamous Cell  -0.04 0.84-1.10 0.59 





-0.12 0.72-1.09 0.26 
Marital Status    




   Single 0.12 0.93-1.35 0.22 
   Divorced, Widowed, 
Separated 
 
-0.07 0.84-1.05 0.25 
Survival Time  
 




Table 2.7 Continued 
 
 
Covariates (N = 1,254) Coefficient(β) (β) 95% CI p Value 
Marital Status    




   Single 0.12 0.93-1.35 0.22 
   Divorced, Widowed, 
Separated 
 
-0.07 0.84-1.05 0.25 
Survival Time  
 
0.00 1.00-1.00 0.35 
Note. Statistically significant at alpha level of 0.05; exp(β) = exponent of log coefficient;  





Adjusted Negative Binomial Regression Model of Total Healthcare Utilization 
 
 
Covariates (N = 1,254) Coefficient(β) (β) 95% CI p Value 
American Indian and 
Alaska Native Race 
 
-0.12 0.81-0.97 0.01 
 
Age at Diagnosis    
  65-70 Reference   
  71-75 -0.04 0.86-1.07 0.42 
  76-80 -0.14 0.77-0.98 0.02 
  81+ -0.23 0.70-0.91 <0.01 
 
Female -0.06 0.86-1.04 0.22 
 
Grade    
  Well Differentiated  Reference   
  Moderately  
     Differentiated  0.04 0.80-1.37 0.76 
  Poorly Differentiated  -0.02 0.75-1.26 0.86 
  Undifferentiated  -0.07 0.69-1.27 0.66 
  Unknown -0.05 0.73-1.23 0.69 
 
AJCC 6th Stage of  
  Disease    
  Stage I Reference   
  Stage II 0.30 1.08-1.69 0.01 
  Stage III 0.26 1.13-1.49 <0.01 
  Stage IV 0.04 0.90-1.19 0.60 
 
Histology Group    
  Adenocarcinoma  Reference   
  Large Cell  0.01 0.80-1.26 0.96 
  Non-Small Cell  0.01 0.88-1.16 0.90 
  Small Cell  0.07 0.93-1.23 0.36 
  Squamous Cell  0.01 0.89-1.13 0.93 





0.09 0.91-1.31 0.36 
 
Marital Status    
   Married, Domestic 
Partner 
Reference   
   Single -0.13 0.75-1.03 0.11 
   Divorced, Widowed, 
Separated 
 








Table 2.8 Continued 
 
 
Covariates (N = 1,254) Coefficient(β) (β) 95% CI p Value 
Marital Status    
   Married, Domestic 
Partner 
Reference   
   Single -0.13 0.75-1.03 0.11 
   Divorced, Widowed, 
Separated 
 




0.00 1.00-1.00 <0.01 
 






HEALTHCARE COSTS AND UTILIZATION DIFFERENCES 
 
BETWEEN AMERICAN INDIANS AND ALASKA 
 
NATIVES COMPARED WITH NON-HISPANIC 
 
WHITES WITH LUNG CANCER DURING 
 





Lung cancer is the leading cause of cancer deaths in the US. Objective: We 
examined total healthcare cost and utilization differences among American Indian and 
Alaska Native patients and non-Hispanic patients in the last six months of life, as well as 
among patients who died and with ≤6 month survival. Methods:  We used the 
Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset and identified 
55,386 patients and of those 627 were matched patients diagnosed from January 1, 2000 
to December 31, 2011. Patients were matched on demographics and cancer prognosis. To 
identify total healthcare costs and total healthcare utilization based on cancer and 
noncancer-treatment, we used diagnosis and procedure codes. To examine total 
healthcare costs between American Indian and Alaska Native patients and non-Hispanic 
White patients, we used a generalized linear model with gamma distribution and log link. 
To examine healthcare utilization, we used a negative binomial regression model. 
Healthcare costs and utilization were analyzed separately by any cause and lung cancer 
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mortality. Results: Being an American Indian and Alaska Native patient was not 
associated with total healthcare costs among any cause and lung cancer mortality  
(p = 0.92, p = 0.97, respectively) after adjusting for patient characteristics, survival time, 
and cancer prognosis. Being an American Indian and Alaska Native patient was not 
associated with healthcare utilization among those who died of any reasons (any cause) 
and those who died of lung cancer (95% CI: 0.85-1.07, 95% CI: 0.81-1.05, respectively) 
compared with non-Hispanic White patients. Conclusion: We conclude there are no 
significant differences in costs or use of care in the last six months of life for AIAN 




Lung cancer is the leading cause of cancer deaths among American Indian and 
Alaska Native (AIAN) patients.42 AIAN patients with cancer have lower 5-year survival 
rates than other racial/ethnic groups.9 AIAN patients more commonly diagnosed with 
lung cancer at late stage (III and IV) compared to other race/ethnicity groups.10 A 
patient’s duration in the terminal illness phase can vary from a few days to a few months 
of life. Patients in the terminal illness or end-of-life phase are those with a poor prognosis 
showing advanced stage of disease when death is likely imminent.  
For patients with advanced lung cancer, end-of-life care helps with the 
management of pain, symptoms, and other psychological, social, spiritual, and practical 
support. It is essential for cancer patients to obtain supportive care while experiencing 
physical and emotional alterations in their remaining days. Cancer patients often 
experience challenges financially, spiritually, and with decisions on proper care.43,44 
Perspectives on end-of-life care among AIAN patients with cancer differ by tribe and 
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cultural influences in the United States.45 AIAN patients experience challenges during the 
end-of-life care due to the idea that talking about death is a taboo, absence of autonomous 
treatment decision making, and existence of medical mistrust and dissatisfaction.46,47 
Once end-of-life care is determined for AIAN elders with lung cancer, little is 
documented on the patterns of healthcare utilization (e.g., inpatient, outpatient, hospice) 
and costs for this population group. Shiovitz and researchers studied cancer-directed 
treatment and hospice care services among lung cancer patients and concluded that 
disparities in hospice utilization are accounted for by socioeconomic status.11  
For many cancer patients, the cost of cancer care is the highest during the end-of-
life period.15 On average, a patient with lung cancer at age 72 in 2000 incurred costs of 
$14,987 in the last month of life.44 In another study, Chastek and researchers reported 
that cancer-related costs in the last six months were $74,212, with rapid increases in 
inpatient costs ($1,785 to $20,559) and hospice services (0.7% to 35.6%).45 In the same 
study, lung cancer patients had an average of $25,529 in inpatient costs and $7,714 in 
outpatient procedures. It is uncertain if older AIAN patients experience lower 
expenditures in the terminal phase compared with non-Hispanic White (NHW) patients. 
Availability of end-of-life care services and use of services among AIAN cancer 
patients are limited. In one study, Kitzes and researchers examined end-of-life and 
palliative care issues at one federally directed Indian Health Service area in the 
Southwest and concluded that there were few formal palliative services available to 
AIAN cancer patients in the mid-1990s.45 Another option for cancer patients in the end-
of-life phase is hospice services that provide support to improve the quality of care in 
their remaining days. Shivotz and researchers reported significant differences in fewer 
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hospice utilization among AIAN elders compared with NHW elders.11 
Healthcare cost and utilization in the last six months of life for AIAN elders with 
early lung cancer stage (stage I and II) to metastatic lung cancer has not been extensively 
researched. The study will examine differences of total healthcare cost and utilization 
during the end-of-life period (i.e., last 6 months of life) between AIAN patients and 




3.3.1 Study Design and Data Source 
 
This study was a cohort design using the Surveillance, Epidemiology, and End 
Results (SEER)-Medicare dataset from 2000 to 2012. SEER-Medicare is a population-
based resource often used cancer epidemiology and health services research. The SEER-
Medicare database represents 26% of the United States population and 42% of the AIAN 
population aged 65 and older based on SEER registry locations.10 This study utilized data 
from SEER registries in Connecticut, Detroit, Greater California, Greater Georgia, 
Hawaii, Iowa, Kentucky, Louisiana, Los Angeles, Michigan, New Jersey, New Mexico, 
Rural Georgia, San Francisco-Oakland, San Jose-Monterey, Seattle-Puget Sound, and 
Utah. The SEER-Medicare dataset was a linked dataset by using a unique patient 
identification number in the SEER Registry and Medicare claims. Several files from 
SEER-Medicare were used in this study: Durable Medical Equipment (DME), Home 
Health (HHA), Hospice (HOSP), Medicare Provider Analysis and Review (MEDPAR), 
National Claims History (NCH, previously known as Physician/Supplier), Outpatient 
(OUTSAF), and Patient Entitlement and Diagnosis File (PEDSF).  
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3.3.2 Study Population 
Non-Hispanic White and AIAN Medicare enrollees aged 65 years or older with a 
first primary cancer date of diagnosis between January 1, 2000 and December 31, 2011 of 
lung and bronchus cancer (e.g., ICD-O codes C34.0-C34.3, C34.8, C34.9) and stages IA 
to IV (as defined by the American Joint Committee on Cancer) were included. Further 
inclusion were patients with continuous enrollment in Part A and Part B six months prior 
to cancer diagnosis date and six months prior to date of death date. If the patient died 
within those timeframes, they were still included in the study. Patients with a Medicare 
date of death were included in the study. 
The following are exclusions of patients based on Medicare enrollment, histology 
of disease and date of cancer diagnosis. Patients were excluded based on Medicare 
eligibility status as a managed care plan and/or absence of any Part A and Part B 
coverage six months prior and after cancer diagnosis. Patients with the following lung 
cancer histology codes were excluded due location of tumor on skin or gastrointestinal 
tract: 8585/3 Thymoma, malignant; 8720/3 Malignant melanoma; 8770/3 Mixed 
epithelial and spindle cell melanoma; 9650/3 Hodgkin lymphoma; 9680/3 Diffuse large B 
cell; and 9699/3 Marginal zone B-cell lymphoma. Patients with a diagnosis date at death 
or autopsy, a cancer diagnosis date after date of death, or a cancer diagnosis date prior to 
age 65 were excluded due to absence of claims data. The resulting sample for this study 
was 443,691 patients and 55,386 patients had a survival time of ≤6 months after cancer 
diagnosis (see Figure 3.1). The matched sample was 209 AIAN patients and 418 patients 
with a ≤6 month survival time. The healthcare utilization and costs differed for patients 
who survived more than six months; this patient group will be explored in a separate 
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analysis and was considered to be beyond the scope of the current study. 
 
3.3.3 Propensity Score Method 
 
We used the propensity score methodology developed by Rosenbaum and Rubin 
who described propensity scores as the probability of treatment assignment conditional 
on observed baseline covariates.26 The propensity scores were applied to improve 
adjustment of confounders, such as marital status and disease attributes, and to establish 
similar matched controls (matching NHW patients to the AIAN patients). Although it is 
important to note that hidden bias (unmeasured confounders) cannot easily be detected 
using this method.27,28 
In this study, logistic regression was used to estimate propensity scores for each 
patient. The covariates were age at diagnosis, sex, year of diagnosis, stage of disease, 
grade, histology, Charlson Comorbidity Index, SEER registry, and marital status. The 
Charlson Comorbidity Index was derived from physician claims of comorbid 
conditions.29-31 The focus of the study consists of stages III to IV lung cancer patients; 
therefore, cancer diagnosis was excluded in the Charlson Comorbidity Index.32 The 
PSMATCH2 in STATA was used for propensity scoring matching of 1:2 ratio without 
replacement.28,33,34 To analyze the propensity scores and to determine similarities, we 
first assessed the balance of covariates, the continuous and categorical covariates means 
and proportions were compared using the Harder, Stuart, and Anthony method along with 







3.3.4 Definition of Total Healthcare Cost 
 
Total healthcare costs were examined for no more than six months, in addition, 
costs were analyzed separately depending on whether the cause of death was lung cancer 
or any cause. To identify total healthcare costs the Current Procedural Terminology 
(CPT), Healthcare Common Procedure Coding System (HCPCS), International 
Classification of Diseases, Ninth Revision (ICD-9), and revenue codes were used (see 
Table 3.1). The DME, HHA, HOSP, MEDPAR, NCH, and OUTSAF files were used to 
estimate total healthcare costs. All healthcare costs for each outpatient and inpatient visit 
were assessed from the patient’s admission date. Total healthcare cost consists of cancer-
treatment and noncancer-treatment costs that are defined as payments and not charges.  
The three payment sources used to identify total healthcare costs in the SEER-
Medicare files are Medicare, coinsurance, and patient responsibility. Medicare costs are 
reimbursed amounts. Coinsurance is payments by a primary payer other than Medicare. 
Patient responsibility is defined as the beneficiary’s liability for payment.  
Total healthcare cost was defined as the sum of cancer-treatment and noncancer-
treatment costs from the SEER-Medicare files. Inpatient, outpatient, and emergency 
department costs were identified from the NCH file. Part A claims using the Centers for 
Medicare and Medicaid Services (CMS) Inpatient Hospital Index and Part B claims were 
adjusted using the Medicare Economic Index.34 All costs were reported in 2012 dollars as 








3.3.5 Definition of Healthcare Utilization 
 
Total healthcare utilization was examined from six months up to date of death 
among those who died of any cause or lung cancer.  Healthcare utilization is defined as 
the sum of cancer-treatment encounters and noncancer-treatment encounters. The NCH 
file was used to identify patient encounters. Encounters were comprised of inpatient (Part 
A), outpatient (Part B), and emergency department (Part B). To identify encounters, the 
ICD-9, revenue, HCPCS, and CPT codes were used. Total healthcare visits were based 




The PEDSF file was used to identify the patient’s age at diagnosis, year of 
diagnosis, sex, stage of disease, histology, SEER registry at diagnosis, and marital status. 
The NCH file was used to identify Charlson Comorbidity Index scores. 
 
3.3.7 Statistical Analysis 
 
To describe patient characteristics, the chi-square test was used to determine 
NHW versus AIAN cohort differences for binary and categorical variables. The 
independent t test was used to examine the differences of continuous variables between 
the cohort groups. Statistical significance was defined as p < 0.05. STATA version 14.0 
(Stata Statistical Software: Release 14. College Station, TX: StataCorp LP) was used for 
all analyses. Healthcare costs and utilization analyses were separated by mortality (any 
cause and lung cancer). To examine total healthcare costs, an estimated generalized linear 
model (GLM) with log link and gamma distribution was applied. To examine the 
associations of healthcare utilization with other variables and due to the over-dispersion 
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(if the variance is larger than the mean of a Poisson distribution) of total healthcare 
utilization, a negative binomial regression model (NBRM) was used in the unadjusted 
and adjusted models. 
3.4 Results 
A total of 55,386 AIAN patients and NHW patients were included in the study. Of 
those, a total of 619 patients were in the matched cohort (209 AIAN patients and 410 
NHW patients).  
3.4.1 Patient Characteristics 
A total of 55,379 patients were available for selection into the study, 216 AIAN 
patients and 55,170 NHW patients (see Table 3.1). Before matching, age at diagnosis  
(p = 0.01), stage of disease (p = 0.04), marital status (p < 0.01), and US census region 
residence (p < 0.01) differed between AIAN patients and NHW patients. There were 
more AIAN patients compared with NHW patients between ages 71 to 75 (30% versus 
25%), had stage IV disease (63% versus 65%), were either divorced/separated/widowed 
(51% versus 41%), and resided in the West US census region (78% versus 34%). Year of 
diagnosis after 2005 (54% versus 49%), adenocarcinoma lung cancer type (27% versus 
30%), lung cancer death (81% versus 85%), grade undetermined (60% versus 61%), 
Charlson Comorbidity Index scores (0.02 versus 0.03), males (51% versus 55%), and 
census metro residence in the west region (78% versus 34%) were similar between AIAN 
patients and NHW patients.  
After patients were propensity score matched, there were 209 AIAN patients and 
418 NHW patients (see Table 3.1). All covariates met the 10% standardized bias criteria 
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between AIAN patients and NHW patients in the propensity score matching method (see 
Figures 3.2 and 3.3). Therefore, no differences were shown for age at diagnosis (p = 
0.33), year of diagnosis (p = 0.78), cause of death (p = 0.10), grade (p = 0.37), baseline 
Charlson Comorbidity Index (p = 0.46), gender (p = 0.46), census tract metro residence 
(p = 0.05), marital status (p = 0.41), while differences existed for stage of disease (p = 
0.02) and US census region (p < 0.001) between AIAN patients and NHW patients.  
The unadjusted differences in mean total healthcare costs after matching was 
$601 ($32,139 versus $31,538 for AIAN and NHW, respectively) (see Table 3.2). In 
Table 3.3, the unadjusted difference in mean total healthcare utilization after matching 
was one visit (26 versus 27 visits for AIAN and NHW, respectively). The mean monthly 
trend for cancer- and noncancer-treatment costs increased up to two months before date 
of death (see Figure 3.4).
3.4.2 Unadjusted Total Healthcare Costs by Cause of Mortality 
The generalized linear regression model was used to identify differences in the 
unadjusted mean total healthcare costs between AIAN and NHW lung cancer patients. In 
the unadjusted model for any cause mortality, being AIAN was not associated with 
higher total end-of-life healthcare costs (coefficient = 0.19, p = 0.77). Similarly, for lung 
cancer mortality, being AIAN was not associated with total end-of-life healthcare costs 
(coefficient = 0.04, p = 0.61).  
3.4.3 Adjusted Total Healthcare Costs by Cause of Mortality 
In the adjusted GLM for any cause mortality, being AIAN was not associated 
with total healthcare costs (coefficient = 0.01, p = 0.92), while holding patient 
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characteristics, cancer prognosis, and comorbidities constant (see Table 3.4).  Equally for 
lung cancer mortality, being AIAN was not associated with total healthcare costs 
(coefficient = -0.003, p = 0.97), while holding patient characteristics, survival time, 
cancer prognosis, and comorbidities constant.  
 
3.4.4 Adjusted Total Healthcare Costs by Stage of Disease 
and Any Cause Mortality 
 
When adjustment variables were added to the GLM for patients who died of any 
cause, being AIAN was not associated with total healthcare costs for stage I, II, and III of 
the disease (stage I/II: p = 0.35, stage III: p = 0.45) (see Table 3.5).  Likewise, among 
patients who died of lung cancer, being AIAN was not associated with total healthcare 
costs for stage I, II, and III disease (stage I/II: p = 0.29, stage III: p = 0.33). For patients 
with stage IV disease, among those with any cause and lung cancer mortality, being 
AIAN was not associated with total healthcare costs (Any Cause: p = 0.53, Lung cancer: 
p = 0.53).  
 
3.4.5 Adjusted Total Healthcare Utilization 
 
In the adjusted model for any cause mortality, being AIAN was not associated 
with healthcare utilization compared with NHW patients (coefficient = -0.04, 95% CI: 
0.81-1.05) (see Table 3.6). Patients over the age of 81 years have a 17% decrease in the 
number of healthcare visits relative to younger individuals. Single patients compared with 
divorced, separated, or widowed cancer patients have 4% decrease in the number of 
healthcare visits.  
In the adjusted model for lung cancer mortality, being AIAN was not associated 
with healthcare utilization compared with NHW patients (coefficient = -0.08, 95% CI: 
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0.81-1.05) (see Table 3.6). Patients age 81 years and older have a 18% decrease in the 
number of healthcare visits than younger patients. Patients with other types of histology 
have a 35% decrease in total healthcare visits than other types of lung cancer.  
 
3.4.6 Cancer- and Noncancer-Treatment Care 
 
Overall costs showed that more than half of total healthcare costs for AIAN 
(67%) and NHW (66%) patients with lung cancer were from noncancer-treatment in 
inpatient care, while outpatient care costs from cancer-treatment were 87% for AIAN and 
91% for NHW lung cancer patients. Of the total cancer-treatment costs, 43% was from 
chemotherapy and 61% from radiation therapy for AIAN lung cancer patients (53% from 
chemotherapy and 50% from radiation for NHW patients). Chemotherapy and radiation 
are offered in outpatient care. 
Patient noncancer-treatment visits were 83% of the total healthcare visits in the 
last six months of life for AIAN lung cancer patients in this study. Sixty-percent of 
noncancer-treatment visits by AIAN lung cancer patients were in inpatient settings and it 




The study sought to compare healthcare costs and healthcare utilization in the last 
six months of life between AIAN patients and NHW patients diagnosed with lung cancer 
who survived up to six months before date of death. AIAN lung cancer patients  





3.5.1 Total Healthcare Costs 
 
The mean total healthcare costs in the last six months of life were lower overall in 
our study compared to other studies.49,50 In most cases, patients with advanced lung 
cancer spend more on end-of-life care and initial care after cancer diagnosis.15 Studies 
similar to our study defined costs differently and may limit our comparability. Total 
healthcare costs are higher in our study compared to Bremner and colleagues, since we 
included stages I to IV disease, patients who received/did not receive health services, all 
lung cancer types, and our definitions of costs differed (e.g., short- and long-term 
inpatient stays were included, and clear distinction of cancer and noncancer-treatment 
costs). However, monthly trends for short-term survival are consistent with our findings, 
noncancer-treatment costs increased from month six up to month two ($1,483 to $11,495 
for AIAN patients, $1,101 to $10,440 for NHW patients) and decreased in the last 30 
days of life. The decrease in the last 30 days of life represent partial costs of patients who 
died after the first day of the month, these are due to SEER releasing only cancer 
diagnosis month and year date, but not diagnosis day.  
In comparison to a study that ended in 2009 by Chastek and colleagues, we 
reported similar monthly trends in the last six months of life for inpatient care, 
chemotherapy and radiation therapy. Their total cancer costs were $58,818, (commercial 
insurance was the primary payer) while our study reported total healthcare costs of 
$32,139 for AIAN and $31,538 for NHW lung cancer patients.49 Although Chastek and 
colleagues49 indicated their results are similar to Medicare costs, the estimates in this 
study of cancer-treatment and noncancer-treatment are not close to their total cancer costs 
of $58,818. Our study was able to separate treatments (cancer and noncancer) and overall 
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health services during the six-month period, whereas prior studies provided estimates of 
cancer costs or specific health services. 
 
3.5.2 Total Healthcare Utilization 
 
Comparability to other studies is limited since prior studies focused on costs in 
the last six months or last year of life and hospice care utilization.49 In our study, a mean 
of one hospice visit for noncancer-treatment was observed in both AIAN and NHW lung 
cancer patients. In contrast, a study by Guadagnolo and researchers51 investigated 
disparities among AIAN patients on Medicare dying from cancer and they reported 
AIAN patients used fewer hospice services compared with NHW patients. Hospice visits 
often decrease hospital days and spending, though, for patients with disenrollment in 
hospice spend more without extending survival time.52-54 Although hospice care is crucial 
during the end-of-life care, 50% of total healthcare visits by AIAN patients and 54% of 
total healthcare visits by NHW patients were from noncancer-treatment care in an 
inpatient setting during the last six months of life in our study.  
Although there are several strengths in this study, some limitations must be 
explained. We used claims data that focus on payments of health services rather than 
clinical reasons. For example, individual medical history and treatment regimen are not 
documented well in claims data. Also, use of claims data introduces coding errors. Since 
patients may or may not use Indian Health Service, our understanding of healthcare 
utilization on and off the Tribal reservations is limited. Payments made by Indian Health 
Service for cancer- and noncancer-treatment are not linked to SEER-Medicare, thus 
Medicare cost estimates are limited and may be underestimated.  Out-of-pocket expenses 
were captured as part of total healthcare costs in this study, but information about receipt 
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of payment is not reported in SEER-Medicare. Most AIAN patients in this study are from 
lower income census regions, however, it’s not known if other financial support 
assistance existed that contributed to their out-of-pocket expenses. For AIAN patients on 
Medicare, more than 28% have no supplemental coverage and are at risk for out-of-
pocket sharing requirements.41 The results in this study may not be generalizable to 
individuals in the general population, since most patients resided in the Western region of 
the United States. Race misclassification is possible, since Medicare uses self-reported 
information, while SEER registries obtain race information from providers.  
In summary, the results in this study verified that despite insignificant differences 
in healthcare costs and utilization between AIAN patients and NHW patients in the last 
six months of life, hospitalizations remain a cost driver in costs. Future research should 
collect data on health costs and utilization to examine specific health services (e.g., 
hospice care use, palliative care access) and socioeconomic factors contributing to worse 
lung cancer survival outcomes for AIAN lung cancer patients. Medicare, Indian Health 
Service, Federal, Tribal, and Private health entities must provide opportunities to increase 
cultural competency of providers to understand end-of-life care resources for AIAN 





Figure 3.1 Inclusion and Exclusions Diagram. 
 




Figure 3.2 Percent of Standardized Bias Differences for  
Propensity Score Matching in Group One. 
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Figure 3.3 Percent of Standardized Bias Differences for  
Propensity Score Matching in Group Two. 
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a) Cancer-Treatment Mean Monthly Costs                     b) Noncancer-Treatment Mean Monthly Costs 
               



































































N = 216 
% 
NHW 
N = 55,170 
% p Value 
AIAN 
N = 209 
% 
NHW 
N = 418 
% p Value 
Age at Diagnosis (mean)   76  0.01 75  76  0.33 
   65-70  75 28.70 13,315 24.13  61 29.19 103 24.64  
   71-75  62 29.63 13,609 24.67  60 28.71 123 29.43  
   76-80  64 19.44 13,313 24.13  41 19.62 87 20.81  
   81+  42 22.22 14,933 27.07 0.05 47 22.49 105 25.12 0.66 
           
Year of Diagnosis           
   2000-2005 99 45.83 2,866 51.23  98 46.89 201 48.09  
   2006-2011 117 54.17 26,904 48.77 0.11 111 53.11 217 51.91 0.78 
           
AJCC 6th Stage of Disease           
   Stage I  13 6.02 3,578 6.49  12 5.74 27 6.46  
   Stage II  10 4.63 1,068 1.94  10 4.78 4 0.96  
   Stage III 58 26.85 14,706 26.66  56 26.79 107 26.79  
   Stage IV  135 62.50 35,818 64.92 0.04 131 62.68 280 62.68 0.02 
           
Histology Type           
   Adenocarcinoma  58 26.85 16,672 30.22  55 26.32 127 30.38  
   Large Cell  10 4.63 2,243 4.07  10 4.78 9 2.15  
   Non-Small Cell  32 14.81 8,677 15.73  30 14.35 75 17.95  
   Small Cell  36 16.67 9,070 16.44  36 17.22 78 18.66  
   Squamous Cell  53 24.54 10,207 18.50  52 24.88 68 16.27  
   Other Type  27 12.50 8,301 15.05 0.28 26 12.44 61 14.59 0.05 
           
Cause of Death           











N = 216 
% 
NHW 
N = 55,170 
% p Value 
AIAN 
N = 209 
% 
NHW 
N = 418 
% p Value 
   Other 41 18.98 8,401 15.23 0.13 39 18.66 57 13.64 0.10 
           
Grade            
   Well Differentiated  5 2.31 947 1.72  5 2.39 3 0.72  
   Moderately   
      Differentiated 
18 8.33 4,651 8.43  17 8.13 32 7.66  
   Poorly Differentiated  49 22.69 12,507 22.67  49 23.44 95 22.73  
   Undifferentiated  14 6.48 3,653 6.62  14 6.70 21 5.02  
   Cell Type Unknown  130 60.19 33,412 60.56 0.98 124 59.33 267 63.88 0.37 




0.02  0.03  0.58 0.02  0.03  0.67 
           
Gender           
   Female 105 48.61 25,036 45.38  101 48.33 215 51.67  
   Male  111 51.39 30,134 54.63 0.34 108 51.67 203 48.33 0.46 
           
Census Tract Residence           
   Metro  163 75.46 43,553 78.94  157 75.12 342 81.82  
   Nonmetro  53 24.54 11,614 21.05  52 24.88 76 18.18  
   Missing 0 0.00 3 0.01 0.45 0 0.00 0 0.00 0.05 
           
Marital Status           
   Married  75 34.72 26,525 48.08  75 35.89 141 33.73  
   Single 23 10.65 3,917 7.10  23 11.00 35 8.37  
   Divorced 111 51.39 22,668 41.09  111 53.11 242 57.89  
   Missing 7 3.24 2,060 3.73 0.001 0 0.00 0 0.00 0.41 
           











N = 216 
% 
NHW 
N = 55,170 
% p Value 
AIAN 
N = 209 
% 
NHW 
N = 418 
% p Value 
US Census Region           
   Northwest  13 6.02 10,941 19.83  13 6.22 74 17.70  
   Midwest 21 9.72 7,844 14.22  21 10.05 88 21.05  
   South 13 6.02 17,730 32.14  13 6.22 88 21.05  
   West 169 78.24 18,655 33.81 <0.01 162 77.51 168 40.19 <0.01 
           












American Indian and Alaska Native Non-Hispanic White 
Mean $ Median $ Range, $ Mean $ Median $ Range, $ 
Unmatched Cohort (AIAN = 216; NHW = 55,170)     
Cancer-Treatment       
Inpatient 401 0 0-13,624 351 0 0-182,457 
Outpatient 3,192 0 0-47,164 3,551 0 0-283,146 
Hospice 18 0 0-3,982 15 0 0-14,559 
Surgery 143 0 0-5,030 135 0 0-182,457 
Radiation 1,647 0 0-33,657 1,767 0 0-61,880 
Chemotherapy 2,139 0 0-29,743 2,298 0 0-283,146 
      Total Cancer-Treatment 3,644 0 0-47,309 3,963 412 4-283,146 
 
Noncancer-Treatment       
Inpatient 21,552 18,637 0-112,359 20,926 14,535 0-664,511 
Outpatient 3,384 2,146 0-23,812 3,229 2,004 0-97,195 
Hospice 1,868 148 0-25,197 2,057 462 0-90,716 
      Total Noncancer 
      Treatment 
 
28,448 23,712 0-121,680 27,909 21,285 0-665,748 
 
Total Healthcare Costs 32,091 26,568 0-126,710 31,873 24,776 0-665,748 
 
Matched Cohort (AIAN = 209; NHW = 418)     
Cancer-Treatment       
Inpatient 405 0 0-13,624 174 0 0-11,043 
Outpatient 3,177 0 0-47,164 3,169 0 0-33,628 









American Indian and Alaska Native Non-Hispanic White 
Mean $ Median $ Range, $ Mean $ Median $ Range, $ 
Surgery 148 0 0-5,029 70 0 0-3,817 
Radiation  1,570 0 0-33,657 1,859 0 0-27,655 
Chemotherapy 2,211 0 0-29,743 1,749 0 0-23,069 
        Total Cancer-Treatment 
 
3,634 0 0-47,309 3,483 0 0-33,643 
Noncancer-Treatment       
Inpatient 21,597 18,914 0-112,359 20,717 13,941 0-221,684 
Outpatient 3,432 2,250 0-23,812 3,221 2,024 0-26,027 
Hospice 1,848 128 0-25,197 3,179 2,011 0-26,027 
          Total Noncancer  
          Treatment 
28,505 23,736 0-121,680 28,055 21,453 0-232,544 
 










































Unmatched Cohort (AIAN = 216; NHW = 55,170)     
Cancer-Treatment       
Inpatient 0.36 0 0-12 0.50 0 0-41 
Outpatient 3 0 0-41 3 0 0-144 
Hospice 0.005 0 0-1 0.005 0 0-4 
Total Cancer-Treatment  3 0 0-41 4 0 0-150 
 
Noncancer-Treatment       
Inpatient 12 10 0-70 13 9 0-244 
Outpatient 7 6 0-52 8 6 0-77 




19 17 0-87 21 17 0-244 
Total Healthcare Visits 
 
24 20 0-93 25 21 0-244 
Matched Cohort (AIAN = 209; NHW = 418)     
Cancer-Treatment       
Inpatient 0.35 0 0-12 0.32 0 0-8 
Outpatient 3 0 0-41 3 0 0-32 
Hospice 0.005 0 0-1 0.01 0 0-2 
Total Cancer-
Treatment  


























Noncancer-Treatment       
Inpatient 12 10 0-70 13 10 0-150 
Outpatient 8 6 0-52 7 5 0-47 




20 17 0-87 20 17 0-152 











Any Cause Mortality (N = 627) Lung Cancer Mortality (N = 531) 
Coefficient(β) exp(β) 95% CI p Value Coefficient(β) exp(β) 95% CI p Value 
American Indian and Alaska  
  Native Race 
 
0.01 0.90-1.13 0.92 -0.003 0.88-1.13 0.97 
Age at Diagnosis       
  65-70 Reference      
  71-75 -0.01 0.86-1.14 0.91 -0.05 0.82-1.11 0.54 
  76-80 -0.06 0.81-1.11 0.48 -0.08 0.78-1.10 0.36 
  81+ -0.10 0.77-1.05 0.19 -0.11 0.75-1.06 0.19 
 
Female -0.02 0.87-1.33 0.89 -0.05 0.84-1.08 0.48 
 
Grade       
  Well Differentiated  Reference      
  Moderately Differentiated  -0.22 0.48-1.33 0.39 -0.14 0.50-1.51 0.62 
  Poorly Differentiated  -0.24 0.48-1.28 0.33 -0.05 0.57-1.61 0.86 
  Undifferentiated  -0.55 0.34-0.98 0.04 -0.33 0.41-1.28 0.26 
  Cell Type Unknown -0.34 0.44-1.15 0.16 -0.14 0.52-1.46 0.61 
 
AJCC 6th Stage of Disease       
 Stage I Reference      
 Stage II -0.36 0.46-1.06 0.10 -0.23 0.49-1.27 0.34 
 Stage III -0.36 0.55-0.88 <0.01 -0.31 0.55-0.98 0.04 
 Stage IV -0.40 0.54-0.85 <0.01 -0.32 0.55-0.96 0.03 
 









Any Cause Mortality (N = 627) Lung Cancer Mortality (N = 531) 
Coefficient(β) exp(β) 95% CI p Value Coefficient(β) exp(β) 95% CI p Value 
Histology Group       
  Adenocarcinoma  Reference      
  Large Cell  -0.17 0.61-1.18 0.33 -0.17 0.59-1.19 0.33 
  Non-Small Cell  -0.21 0.69-0.96 0.02 -0.25 0.65-0.94 0.01 
  Small Cell  -0.03 0.82-1.15 0.73 -0.06 0.78-1.13 0.51 
  Squamous Cell  -0.11 0.76-1.05 0.18 -0.11 0.75-1.07 0.24 
  Other Type  -0.32 0.61-0.87 <0.01 -0.27 0.62-0.93 0.01 
 
Charlson Comorbidity Index  -0.33 0.55-0.94 0.02 -0.36 0.52-0.95 0.02 
 
Marital Status       
   Married  Reference      
   Single 0.17 0.97-1.45 0.09 0.21 0.99-1.53 0.07 




0.13 1.10-1.18 <0.01 0.14 1.11-1.19 0.00 
Constant 10.77   10.51 
 
  




















Coefficient(β) p Value 
Unadjusted       
AIAN Race Stage I and II  53 -0.22 0.41 38 -0.16 0.61 
AIAN Race Stage III  163 -0.07 0.53 138 -0.11 0.38 
AIAN Race Stage IV 407 0.08 0.27 355 0.11 0.17 
 
Adjusted       
AIAN Race Stage I and II  53 -0.27 0.35 38 -0.35 0.29 
AIAN Race Stage III  163 -0.09 0.45 138 -0.13 0.33 
AIAN Race Stage IV 411 0.05 0.53 355 0.07 0.39 
 
                        Note. Statistically significant at alpha level of 0.05; Adjusted model includes: Age, Gender, Grade, Histology, 









Adjusted Negative Binomial Regression Model (NBRM) of Total 
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DEPRESSION INCIDENCE, DEPRESSION TREATMENT  
 
UTILIZATION, AND RISK FACTORS FOR DEPRESSION 
 





Depression disorders are a concern for newly diagnosed AIAN and NHW lung 
cancer patients. Incidence of depression disorders play an important role in lung cancer 
survival. Objective: We evaluated incidence of depression and depression treatment 
utilization 60 months after lung cancer diagnosis. We examined risk factors for 
depression 60 months after lung cancer diagnosis. Methods: We used the Surveillance, 
Epidemiology, and End Results (SEER)-Medicare dataset and identified 121,282 patients 
diagnosed from January 1, 2000 to December 31, 2011.  A Cox proportional hazards 
regression model was used to identify risks for depression. Results: The incidence of 
depression was 3.67% for American Indian and Alaska Native patients and 6.16% for 
non-Hispanic White patients. The mean depression treatment visits were 3.67 for 
American Indian and Alaska Native patients and 2.97 for non-Hispanic White patients. 
American Indian and Alaska Native patients were not at increased risk for depression 
after cancer diagnosis after controlling for patient characteristics and cancer prognosis. 
Conclusion: AIAN patients are not at increased risk for depression disorders. AIAN 
patients suggest a higher percentage of incidence of depression disorders than NHW 
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patients. Further research should focus on improvement of incidence and prevalent rates 




Depression disorders is a major concern for patients among those recently 
diagnosed with lung cancer. A study reported that older patients with major depression 
disorders within eight weeks of metastatic non-small cell lung cancer diagnosis had 
shorter survival (i.e., 5.4 months major depression disorders, 10 months no major 
depression disorder).16 Also, patients newly diagnosed with invasive small and non-small 
cell lung cancer with depression symptoms had significantly higher mortality when more 
cancer symptoms were present (p = 0.01) and when patients had less social support  
(p = 0.04).57 Depression symptoms coexist with other health conditions in some older 
adults as part of aging. It is often undiagnosed but when experiencing a new cancer 
diagnosis it could exacerbate depression symptoms.58,59 Certain older patients are more at 
risk of the onset of depression. Lung cancer patients who are female, low income, not 
married, less educated, and currently smoke were associated with a higher chance of 
depression symptoms.57,60  
Depression, anxiety, and serious psychological distress are higher for American 
Indian and Alaska Native (AIAN) adults without cancer when compared to other 
racial/ethnicity groups.61 It is unclear if racial differences in mental health issues exist 
among individuals with cancer; furthermore, little is known of AIAN elderly patients.62-64 
Studies of incidence rate of depression disorders and risk factors do not exist for AIAN 
elderly with lung cancer and it is often recommended by other researchers as a step in 
understanding mental health issues.65 As well, documentation of depression treatment is 
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not known for AIAN lung cancer patients.58,66-68  
The aim is to compare the incidence rates of depression disorders and depression 
treatment utilization 60 months (5 years) following lung cancer diagnosis among AIAN 
and non-Hispanic White (NHW) patients. The hypotheses are that AIAN patients will 





4.3.1 Study Design and Data Source 
 
This study was a cohort design using the Surveillance, Epidemiology, and End 
Results (SEER) Medicare dataset from 2000 to 2012. SEER-Medicare is a population-
based resource in cancer epidemiology and health services research. The SEER-Medicare 
database represents 26% of the United States population and 42% of the AIAN 
population aged 65 and older based on SEER registry locations.10 This study utilized data 
from SEER registries in Connecticut, Detroit, Greater California, Greater Georgia, 
Hawaii, Iowa, Kentucky, Louisiana, Los Angeles, Michigan, New Jersey, New Mexico, 
Rural Georgia, San Francisco-Oakland, San Jose-Monterey, Seattle-Puget Sound, and 
Utah. The SEER-Medicare dataset was a linked dataset by using a unique patient 
identification number in the SEER Registry and Medicare claims. Several files from 
SEER-Medicare were used in this study: Durable Medical Equipment (DME), Home 
Health (HHA), Medicare Provider Analysis and Review (MEDPAR), National Claims 
History (NCH, previously known as Physician/Supplier), Outpatient (OUTSAF), and 




4.3.2 Study Population 
 
Non-Hispanic White and AIAN Medicare enrollees aged 65 years or older with a 
first primary cancer date of diagnosis between January 1, 2000 and December 31, 2011 of 
lung and bronchus cancer (i.e., ICD-O codes C34.0-C34.3, C34.8, C34.9) and stages IA 
to IV (as defined by the American Joint Committee on Cancer) were included. Further 
inclusion were patients with continuous enrollment in Part A and Part B from the cancer 
diagnosis date to at least 12 months before and after cancer diagnosis were included in 
the study. If patients died during the Part A and B time frame, they were included in the 
study.  
The following are exclusions of patients based on Medicare enrollment, histology, 
and date of cancer diagnosis. Patients were excluded based on Medicare eligibility status 
as a managed care plan and/or absence of any Part A and Part B coverage up to 12 
months prior to and 12 months following cancer diagnosis. Patients with lung cancer 
histology codes that were excluded due to origin of tumor location and different 
treatments: 8585/3 Thymoma, malignant; 8720/3 Malignant melanoma; 8770/3 Mixed 
epithelial and spindle cell melanoma; 9650/3 Hodgkin lymphoma; 9680/3 Diffuse large B 
cell; and 9699/3 Marginal zone B-cell lymphoma. Patients with a diagnosis date at death 
or autopsy, a cancer diagnosis date after date of death, or a cancer diagnosis date prior to 
age 65 years were excluded due to absence of claims data.  The resulting sample for this 
study was 443,691 subjects and 312,870 were excluded. The sample was a total of 







4.3.3 Definition of Depression Disorders 
 
To identify depression disorders, the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis codes by the American 
Psychiatric Association were aligned with the International Classification of Diseases, 
Ninth Revision (ICD-9) codes. Patients were considered to have a depression disorder 
diagnosis if at least one claim in an inpatient or outpatient setting included the following 
ICD-9 codes: 296.2 - 296.25 (major depressive disorder), 300.4 (dysthymic depression), 
309.1 (prolonged depressive reaction), and 311.0 (depressive disorder, not otherwise 
specified). Similar studies of depression and cancer used the ICD-9 codes mentioned.58,69 
 
4.3.4 Definition of Depression After Cancer Diagnosis 
 
Patients with no depression disorder at cancer diagnosis date were examined after 
lung cancer diagnosis. The focus of determining depression at cancer diagnosis was to 
isolate patients with depression disorder after cancer diagnosis from those with a history 
of any depression symptoms. Patients with previous depression may have reoccurring 
depression disorder and often experience different symptoms and treatment strategies 
compared to patients newly diagnosed with a depression disorders.70 
 
4.3.5 Definition of Depression Treatment Utilization 
 
Depression treatment utilization of patients with depression were examined within 
60 (5 years) months following lung cancer diagnosis. Patients with new incidence of 
depression disorder and patients with depression disorders before cancer diagnosis were 
analyzed for depression treatment utilization.  Depression treatment utilization was 
defined as mean and median visits. The classification of depression treatment visits 
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(psychiatry and evaluation and management codes) occurred in outpatient and inpatient 
settings. The Current Procedural Terminology (CPT) codes by the American Medical 
Association were used to identify claims for psychiatric or pharmacological treatment for 
depression disorder and/or other health conditions at a hospital/clinic visit. The following 
CPT codes were used: 90801, 90804, 90805, 90806, 90807, 90862, 99201-99205, 99212-
99215, 99241-99245, 99218-99223, and 99231-99238.69 Psychiatry codes used in this 
study are 90801 to 90862 and codes 99201 to 99238 relate to evaluation and management 
services for counseling or coordination of care by Medicare providers.  Depression 
treatments are typically provided by mental health professionals and other clinical 
providers. 
 
4.3.6 Statistical Analysis 
 
A summary of patient characteristics was calculated for all patients and those with 
depression in the cohort after cancer diagnosis. Additionally, lung cancer-treatment and 
depression diagnosis before or after treatment were described. The chi-square test was 
used to determine cohort differences for binary and categorical variables. The 
independent t test was used to examine the differences of continuous variables between 
the cohort groups. Fisher’s exact test was used to compare differences for cells with less 
than five patients. The Charlson Comorbidity Index was derived from physician claims of 
comorbid conditions.32-34 To investigate risk factors among all patients for depression 
disorder, a Cox proportional hazards regression model was used for analysis. Statistical 
significance was defined as p < 0.05. STATA version 14.0 (Stata Statistical Software: 






In this study there were 121,282 patients diagnosed with lung cancer from 2000 to 
2011, 409 AIAN patients and 120,973 NHW patients. Patients with depression disorder 
after cancer diagnosis totaled 7,467 patients, 15 AIAN patients and 7,452 NHW patients.  
AIAN patients were not significantly different than NHW patients in terms of 
gender (p = 0.95), Charlson Comorbidity Index (p = 0.92), and year of diagnosis  
(p = 0.14) (see Table 4.1). Whereas, the AIAN patients and NHW patients significantly 
differed in age (p = 0.01), stage of disease (p = 0.03), histology (p = 0.01), marital status 
(p < 0.01), census median income (p < 0.01), and US Census Region (p < 0.01). Overall, 
there were more males (52% AIAN, 52% NHW) than females (48% AIAN, 48% NHW), 
more with stage IV disease (46% AIAN, 45% NHW), diagnosed with cancer after 2004 
(54% AIAN, 51% NHW), and had more than one comorbidity condition (54% AIAN, 
54% NHW) among both cohorts. NHW patients resided in a higher census median 
income area than AIAN patients ($49,055 NHW versus $39,495 AIAN).  
 
4.4.1 Depression After Cancer Diagnosis 
 
Of the 121,282, there were 15 (3.67%) AIAN patients and 7,452 (6.16%) NHW 
patients with depression after cancer diagnosis (see Table 4.2). AIAN patients and NHW 
patients were similar in age (p = 0.40), gender (p = 0.05), stage of disease (p = 0.09), year 
of diagnosis (p = 0.35), marital status (p = 0.90), and Charlson Comorbidity Index  
(p = 0.44). More patients with depression were younger than 70 years old (40% AIAN, 
37% NHW), diagnosed after 2005 (67% AIAN, 55% NHW), were married (60% AIAN, 
54%), had more than one comorbidity (40% AIAN, 52% NHW), and resided in the West 
US Census Region (73% AIAN, 34% NHW). The difference in census median income 
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was fewer for AIAN patients than NHW patients ($37,234 AIAN versus $50,213).  
 
4.4.2 Lung Cancer-Treatment and Depression Diagnosis 
 
Of the 121,282 patients, 61% of AIAN patients and 66% of NHW patients 
received one or more types of cancer-treatment (i.e., surgery, radiation, chemotherapy) 
(see Table 4.2). The incidence of depression over 5-years after lung cancer diagnosis was 
3.67% for AIAN patients and 6.16% for NHW patients. Among those with depression 
after cancer diagnosis, 13 (87%) AIAN patients and 6,083 (82%) received one or more 
types of cancer-treatment. Eighty-seven percent (n = 13) of AIAN patients and 68%  
(n = 5,095) of NHW patients were diagnosed with depression after cancer diagnosis. 
 
4.4.3 Depression Treatment Utilization 
 
In Table 4.3, among patients with an incidence of depression disorder, their mean 
visits for depression treatment for the AIAN patients compared with the NHW patients 
(3.67 AIAN versus 2.97 NHW), and the median number of visits was 3.0 for AIAN 
patients and 1.0 for NHW patients. Among prevalent cases of depression disorders, 
AIAN patients had eight mean depression treatment visits and NHW patients had 4.61 
visits for depression treatment. 
 
4.4.4 Risk Factors for Depression 
 
In Table 4.4, the Cox proportional hazards regression model is considered for this 
analysis to relate risk factors to depression disorders. In the unadjusted model, AIAN 
patients had an increased risk depression disorder compared with NHW patients (HR: 
1.37, 95% CI: 0.94-2.59). Similarly, after adjusting in model one for patient 
characteristics, comorbidities, and cancer prognosis, AIAN patients were not at increased 
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risk for depression disorders compared with NHW patients (HR: 1.40, 95% CI: 0.84-
2.33). In model two, adding census median income of <$44,500 versus >$44,499, AIAN 




The study was to examine incidence of depression disorder following 60 months 
after cancer diagnosis, as well to determine depression treatment utilization and risk 
factors for depression disorder. We concluded a lower proportion of incidence of 
depression disorders for AIAN patients than NHW patients, but AIAN patients suggest a 
higher proportion of healthcare utilization for depression treatment services following 
cancer diagnosis. When we examined risk factors, AIAN patients suggest a higher risk 
for depression disorder, but it was not significant. AIAN patients are diagnosed with 
depression disorders close to their cancer diagnosis date, while NHW patients are 
diagnosed up to 60 months. A study by Sullivan and colleagues concluded that being 
younger, female, low income, and unmarried had a higher chance of depression 
symptoms at five and 12 months after cancer diagnosis.57 The results suggest a higher 
proportion of females who had a depression disorder before cancer diagnosis and a higher 
proportion of males who had a depression disorder after cancer diagnosis.  
While studies of risk factors indicate certain similarities to this study, the 
incidence rates of depression disorder are lower compared to other studies. The majority 
of the research in the United States focuses on the prevalence of depression among cancer 
patients.71 For example, a head and neck cancer study using SEER-Medicare data with 
similar methodologies examined preexisting and new depression diagnosis. They 
concluded that 10.6% of patients had preexisting depression and 8.9% of patients had 
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new depression after head and neck cancer diagnosis.71 The depression rates in the head 
and neck cancer study were higher; this could be due to their expanded number of 
depression diagnosis codes that included adjustment disorder with depressive symptoms 
and depressive personality disorders. In another United States study, 66 researchers 
examined the association of patient characteristics with chemotherapy among depressed 
and nondepressed Veteran patients with advanced non-small cell lung cancer patients. 
Researchers concluded that 16% (1,966) of cancer patients had depression and of those 
36% (698 out of 1,966) received chemotherapy, but the study did not indicate if 
chemotherapy was before or after depression diagnosis.66 The need for studies of 
incidence and prevalence of depression disorders among cancer patients has been widely 
recognized by researchers.  
Consequently, more international researchers are investigating the incidence of 
depression after lung cancer diagnosis with consideration of cancer-treatment time 
periods.72,73 For instance, investigators from Japan conducted a 12-month follow-up after 
curative surgery of adult lung cancer patients and they concluded that prevalence of 
depression did not change after resection. A limitation of their study was information 
about preexisting depression before surgery.73 Another study published by researchers 
from South Korea showed that 12% of lung cancer patients had preoperative depression 
and this increased to 19% of patients who had postoperative depression upon surgical 
treatment.72 Additional research in the United States on depression disorders before and 
after cancer-treatment can contribute to patient survival.  
Inconsistent findings of prevalence rates of depression disorders among cancer 
patients are discussed among researchers rather than incidence rates of depression 
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disorders. Accordingly, a systematic review of depression in adults with cancer 
concluded that prevalence of depression in outpatients were between 5% to 16%, whereas 
rates in inpatients were between 4% to 11%. Researchers who contributed to the 
systematic review suggested that there needs to be consistent measurements and a 
definition for depression among cancer patients or else prevalence estimates across 
studies remain noncomparable.17,74 Another meta-analysis on prevalence of depression in 
cancer patients echoed similar recommendations that differences in prevalence rates are 
caused by the type of instrument, cancer type and phases of treatment. In their study, 
prevalence of depression in cancer patients ranged from 8% to 24%.18 
Another aspect of this study was to examine depression treatment utilization after 
lung cancer diagnosis. On average, patients who visited a provider more than once for 
depression were similar to one study, researchers reported that 55% of lung cancer 
patients diagnosed with depression after cancer diagnosis had more than one mental 
health visit.66 Although 84% of AIAN patients received more than one visit for 
depression, their visits ended soon after cancer diagnosis. One NHW patient in this study 
visited a provider for depression 233 times, while an AIAN patient visited only 13 times.  
A limitation of this study is the use of claims data to determine depression among 
lung cancer patients. Claims data can be influenced by coding errors. We were not able to 
conduct baseline and follow-up using established diagnostic tools, such as Patient Health 
Questionnaire (PHQ-9) or interviews. Geographically, representation of AIAN patient 
who utilize Indian Health Service is limited since Indian Health Service Contract Health 
Service Delivery Areas are not aligned with SEER registry locations. A strength of the 
study is addressing a gap in knowledge of incidence and prevalence of depression that 
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can serve as preliminary data for future studies to address disparities between AIAN and 
NHW patients.  
We found evidence to encourage providers to continually screen and support 
treatment of depression for lung cancer patients throughout their cancer care. As well as 
to focus on screening for depression among female AIAN patients and before cancer-
treatment, since there were no AIAN lung cancer patients who were diagnosed with 
depression before cancer-treatment. Similar studies need to be conducted to provide 
comparisons across racial/ethnicity groups.  Future research should consider 












(N = 409) 
AIAN Depression 
(N = 15 of 409) 
N % N % 
Age at Diagnosis (Mean, yrs) 74  72  
  65-70 years 135 33.01 6 40.00 
  71-75 years 121 29.58 6 40.00 
  76-80 years 84 20.58 2 13.33 
  81+ years 69 16.87 1 6.67 
 
Gender     
  Female 195 47.58 5 33.33 
  Male 214 52.32 10 66.67 
 
AJCC 6th Stage of Disease     
  Stage I 67 16.38 2 13.33 
  Stage II 23 5.62 1 6.67 
  Stage III 130 31.78 8 53.33 
  Stage IV 189 46.21 4 26.67 
 
Year of Diagnosis     
  2000-2005 187 45.72 5 33.33 
  2006-2011 222 54.28 10 66.67 
 
Histology     
  Adenocarcinoma 114 27.87 3 20.00 
  Large Cell 15 3.67 0 0.00 
  Non-Small Cell 74 18.09 2 13.33 
  Small Cell 64 15.65 6 40.00 
  Squamous Cell 103 25.18 4 26.67 
  Other Type 39 9.54 0 0.00 
 
Marital Status     
  Married 166 40.59 9 60.00 
  Single 37 9.05 1 6.67 
  Divorced 191 46.70 5 33.33 
  Unknown 15 3.67 0 0.00 
 
Census Median Income (2000) ($) 39,495  37,234  
  Missing  3  0 
 
 
Baseline Charlson Comorbidity 
Index 
    
  0  67 16.38 4 26.67 
  1 120 29.34 5 33.33 
  ≥2 222 54.28 6 40.00 
US Census Region     
  Northwest 28 6.85 2 13.33 
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(N = 409) 
AIAN Depression 
(N = 15 of 409) 
N % N % 
  Midwest 33 8.07 1 6.67 
  South 22 5.38 1 6.67 
  West 326 79.71 11 73.33 
 
Depression Disorder at Cancer 
Diagnosis 
    
Yes 26 6.36 -  
No 383 93.64 -  
 










(N = 120,973) 
NHW Depression 
(N = 7,452 of 120,973) 
N % N % 
Age at Diagnosis (Mean, 
yrs) 75  
74  
  65-70 years 35,976 29.74 2,719 36.49 
  71-75 years 31,482 26.02 2,066 27.72 
  76-80 years 27,685 22.89 1,545 20.73 
  81+ years 25,830 21.35 1,122 15.06 
 
Gender     
  Female 57,498 47.53 4,352 58.40 
  Male 63,475 52.47 3,100 4,352 
 
AJCC 6th Stage of Disease     
  I 26,626 22.01 3,013 40.43 
  II 5,281 4.37 559 7.50 
  III 34,859 28.82 2,043 27.42 
  IV 54,207 44.81 1,837 24.65 
 
Year of Diagnosis     
  2000-2005 59,739 49.38 3,373 45.26 
  2006-2011 61,234 50.62 4,079 54.74 
 
Histology     
  Adenocarcinoma 43,346 35.83 3,315 44.48 
  Large Cell 4,524 3.74 265 3.56 
  Non-Small Cell 16,493 13.63 766 10.28 
  Small Cell 17,724 14.65 869 11.66 
  Squamous Cell 27,055 22.36 1,866 25.04 
  Other Type 11,831 9.78 371 4.98 
 
Marital Status     
  Married 63,629 52.60 4,057 54.44 
  Single 7,914 6.54 417 5.60 
  Divorced 45,184 37.35 2,770 37.17 
  Unknown 4,246 3.51 208 2.79 
 
Census Median Income  
   (2000 $) 
49,055  50,213  




    
  0  19,031 15.73 1,160 15.57 
  1 36,219 29.94 2,394 32.13 
  ≥2 65,723 54.33 3,898 52.31 
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(N = 120,973) 
NHW Depression 
(N = 7,452 of 120,973) 
N % N % 
US Census Region     
  Northwest 25,158 20.80 1,541 20.68 
  Midwest 17,361 14.35 1,045 14.02 
  South 38,026 31.43 2,348 31.51 
  West 40,428 33.42 2,518 33.79 
 
Depression Disorder at 
Cancer Diagnosis 
    
  Yes 7,371 6.09 - - 
  No 113,602 93.91 - - 
 
           Note. AIAN = American Indian and Alaska Native; NHW = Non-Hispanic White.  









(N = 409) 
AIAN Depression 
(N = 15 of 409) 
NHW All 
(N = 120,973) 
NHW Depression 
(N = 7,452 of 120,973) 
N % N % N % N % 
Surgery         
  Yes 51 12.47 4 26.67 20,750 17.15 2,562 34.38 
  No 358 87.83 11 73.33 100,223 82.85 4,890 65.62 
 
Radiation         
  Yes 178 43.52 9 60.00 48,886 40.41 3,387 45.45 
  No 231 56.48 6 40.00 72,087 59.59 4,065 54.55 
 
Chemotherapy         
  Yes 141 34.47 5 33.33 46,123 38.13 3,321 44.57 
  No 268 65.53 10 66.67 74,850 61.87 4,131 55.43 
 
Any Cancer-treatment         
 Yes 252 61.61 13 86.66 80,074 66.19 6,083 81.63 
 No 157 38.39 2 13.33 40,899 33.81 1,369 18.37 
         
New incidence of depression before cancer-treatment 
 
-  0 0.00 -  988 13.26 
New incidence of depression after cancer-treatment 
 
-  13 86.66 -  5,095 68.37 
New incidence of depression and no cancer-treatment 
 
-  2 13.33 -  1,369 18.37 










Depression Treatment Utilization 60 Months Following Cancer Diagnosis 
 
 
a) Utilization of Among Those With Depression Disorders After Cancer Diagnosis 
Depression Treatment Utilization 
AIAN (N = 15) NHW (N = 7,452) 
Mean Visits Median Visits Range Mean Visits Median Visits Range 
 
At least one visit 
 
3.67 3 1-13 2.97 1 1-233 
 
b) Utilization of Depression Treatment Among Those With Depression Disorders Before Cancer Diagnosis 
Depression Treatment Utilization 
AIAN (N = 11) NHW (N = 3,187) 
Mean Visits Median Visits Range Mean Visits Median Visits Range 
 
At least one visit 
 
8.00 2 1-30 4.61 2 1-255 








Cox Proportional Hazards Model, Risk Factors for Depression 
 
 
Covariates (N = 7,467) 





















AJCC 6th Stage of Disease      
  Stage I 1.00  1.00  
  Stage II 1.22 1.11-
1.34 
1.22 1.11-1.33 
  Stage III 1.42 1.34-
1.50 
1.42 1.34-1.50 




Histology      
  Adenocarcinoma 1.00  1.00  
  Large Cell 1.16 1.03-
1.32 
1.16 1.02-1.32 
  Non-Small Cell 1.14 1.05-
1.24 
1.13 1.05-1.23 
  Small Cell 1.18 1.09-
1.28 
1.17 1.09-1.27 
  Squamous Cell 1.10 1.04-
1.17 
1.09 1.03-1.16 




Marital Status     
  Married 1.00  1.00  
  Single 1.12 1.01-
1.23 
1.11 1.00-1.23 
   Divorced, Widowed,   
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Table 4.5 Continued 
 
 
Covariates (N = 7,467) 







Charlson Comorbidity Index      
  0 1.00  1.00  










     
Census Median Income   
<$44,500 vs >$44,499 












The purpose of this study was to examine differences in healthcare cost and 
utilization 12 months after lung cancer diagnosis and in the last six months of life among 
AIAN patients compared with NHW patients. Furthermore, to compare the incidence of 
depression, use of mental health services, and the risk for depression 60 months after lung 
cancer diagnosis in the two groups. The results suggest that a higher proportion of AIAN 
patients in the matched sample was diagnosed at stages III or IV disease than stages I and 
II disease. Non-small cell lung cancer is more common in the United States.75 The 
histology suggests a higher proportion of AIAN patients in the matched sample had non-
small cell lung cancer (e.g., adenocarcinoma, squamous, large cell, and non-small) 
compared to small cell lung cancer. We examined disparities between AIAN and NHW 
lung cancer patients with Medicare coverage in their healthcare spending and use of 
health services. We found lower total healthcare spending, for cancer-treatment or 
noncancer-treatment, among AIAN patients with lung cancer 12 months after cancer 
diagnosis. Our results add to broader cost and care studies using SEER-Medicare data 
and provide evidence of racial differences in cost and utilization of health services that 
challenge the CMS and IHS to continue to reduce health disparities.14,15,76 
 The study results support the hypotheses that AIAN patients spent less and 
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visited providers fewer times than NHW patients for total healthcare and cancer-
treatment care 12 months following date of cancer diagnosis. When determining 
racial/ethnic disparities of AIAN elderly, it is important to consider whether 
socioeconomic conditions help to explain the differences, since they generally have lower 
income and less education than NHW. We were able to adjust for median census tract 
level income and marital status in Chapter 4 (depression risk). In Chapters 2 and 3, we 
matched and adjusted on marital status. The claims dataset provided socioeconomic 
variables of the zip code or census tract in which the patients lived, but not for the 
individuals themselves. Future research will need individual information on AIAN 
patients to investigate the relative contributions of race and socioeconomic status to 
disparities to their healthcare costs and utilization.  
This study is one of the first studies to our knowledge to examine total healthcare 
costs from cancer and noncancer-treatment care. Our findings are consistent with those of 
national spending by Medicare that determined that hospitalizations (either cancer- or 
noncancer-treatment care) as the cost driver of total Medicare costs of individuals.77 In 
this study hospitalizations suggest a higher cost of noncancer-treatment costs than for 
cancer-treatment costs among AIAN and NHW lung cancer patients.  We did not 
examine specific diagnosis and procedure codes of the noncancer-treatment care. The top 
five most expensive conditions in inpatient care among Medicare patients are septicemia, 
acute myocardial infarction, acute cerebrovascular disease, diabetes mellitus and those 
with complications and congestive heart failure.77 Future research should focus on 




In Chapter 3, AIAN patients did not have lower total healthcare costs or 
utilization in the last six months of life among those with short survival (at or less than 
six months). The study results did not support our hypotheses that AIAN patients spent 
less and visited a provider fewer times than NHW patients for cancer-treatment and 
noncancer-treatment care.  Due to insignificant differences in healthcare costs and 
utilization between AIAN and NHW lung cancer patients during the first six months after 
diagnosis, further research needs to focus on end-of-life costs at longer intervals of time 
after diagnosis, as well as the quality of care in cancer-treatment and noncancer-treatment 
care since AIAN lung cancer patients have lower 5-year lung cancer survival outcomes. 
In this study, we were not able to examine differences of specific health services among 
AIAN and NHW lung cancer patients, yet the proportion of total healthcare costs for 
inpatient care from noncancer-treatment was highest across all patients. These results 
were similar to Chapter 2; therefore, future research of specific health service disparities 
is recommended. It is possible to increase the study time period to the last year before 
date of death, examine hospice and palliative care in the cultural context, and to consider 
geographic differences in the future.  
In Chapter 4, AIAN patients with lung cancer were not at risk for depression 
disorders and had a lower proportion of incidence rates compared with NHW lung cancer 
patients. External factors, such as measurement of depression disorders and 
understanding of depression among AIAN patients, may affect rates. It is ideal to use 
questionnaires or conduct interviews to collect accurate depression disorder symptoms, 
but due to the claims database used in this study, this is a limitation. More males in this 
study were diagnosed with depression disorders after cancer-treatment and diagnosis. The 
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stigma linked to mental health is another concern in AIAN communities, but cannot be 
explained in this study due to the dataset.  Lastly, adequate mental professionals to 
provide depression treatment services and detect depression disorder through culturally 
appropriate screening is another concern. Information regarding mental health 
professional shortage could help explain these differences and the limitation of effective 
screening tools in AIAN communities. Co-pay for mental health services can be an 
obstacle due to monetary reasons, since AIAN patients with depression came from census 




This analysis concentrated on older patients with Medicare coverage and fee-for-
service payments. Managed care plans are encouraged to find more cost-efficient ways to 
pay providers for services; however, these different ways of payment are then difficult to 
assign to individual care in datasets. Medicare enrollees with fee-for-service coverage can 
purchase supplemental private insurance that covers additional health services options. 
Although supplemental insurance and other payer data were available in the Medicare-
SEER data, due to inaccuracies and incompleteness of such payer data without data from 
the supplemental insurance payer, there was no value in analyzing other payer services 
and costs. Payments by Medicare, other private insurance payers, and patients were 
examined.  Tribal AIAN patients receive primary care health services from the Indian 
Health Service through their tribes either directly in IHS or tribal facilities, and they can 
receive more specialized care from non-IHS or tribal providers through contractual 
payments. For tribal AIAN with Medicare coverage the IHS and tribal facilities and the 
tribes try to bill Medicare for all covered primary and specialized services. However, 
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some suggest that total healthcare costs are not truly represented for Medicare-covered 
AIAN patients with access to IHS services. The IHS CHSDA boundaries are partially 
represented in SEER-Medicare regions in this study; therefore, results may not reflect the 
entirety of AIAN receiving IHS services. In addition, SEER registries are not located in 
all states. Most of the AIAN patients in the SEER data used in this study are represented 
in the West (New Mexico and California, as well as Seattle and other metro areas); 
therefore, the results in this study are not generalizable to all elders.  Most important, it 
was beyond the scope of this study to investigate the types or quality of cancer-treatment 
that the patients received but future studies could benefit from unencrypted provider and 
zip code information, plus specific quality of care measures defined for cancer care for 




 It is important to investigate specific health services that contributed to 
differences in costs and utilization for AIAN patients and NWH patients. 
Recommendations for future Medicare, Indian Health Service, State, Federal, and Tribal 
Actions:  
• Understand supplemental insurance and other payment resources to determine 
if co-pays are an obstacle to treatment and other health services. 
• Develop culturally appropriate materials to explain cancer-treatment options 
for all AIAN elders and for those who speak their native language. 




• Support adequate and accessible services for cancer patients, such as, hospice, 
nursing facilities, and home health. 
Recommendations for future health care delivery and provider actions:  
• Providers receive training to increase awareness of cultural practices and needs 
versus Western practices regarding cancer-treatment and patient perspectives 
related to cancer-treatment.  
• Providers must continually screen for depression throughout cancer care using 
questionnaires or interviews that are culturally appropriate. 
• Providers must conduct follow-up for depression treatment more often. 
Recommendations for future research: 
• Understand specific noncancer-treatment cost differences by using diagnosis 
and procedure codes. 
• Incorporate social behaviors and risk factors (i.e., current smoking) in addition 
to costs and utilization measures. 
• Conduct a study using claims data from certain health care facilities. 
Oversampling methods will increase AIAN representation. Include different 
payers to assess costs, such as out-out-pocket, private insurance, and public 
programs. 
• Design mixed method studies to incorporate patient perspectives  
• Improve self-report on the incidence of depression disorders and seek 
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